Search Result

Results for "

Ischemic

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (6) Adenosine Deaminase (1) Adenosine Receptor (4) Adrenergic Receptor (15) Akt (15) Amino Acid Decarboxylase (1) Aminopeptidase (1) AMPK (7) Amyloid-β (6) Angiotensin Receptor (1) Angiotensin-converting Enzyme (ACE) (5) Antibiotic (5) AP-1 (1) Apoptosis (69) Aquaporin (1) ASK1 (2) ATP Synthase (4) Autophagy (7) Bacterial (8) Bcl-2 Family (7) Beta-secretase (2) Biochemical Assay Reagents (9) Cadherin (1) Calcium Channel (20) CaMK (1) Carboxypeptidase (1) Casein Kinase (2) Caspase (28) CaSR (2) CDK (1) Cholinesterase (ChE) (1) Collagen (1) COX (8) Creatine Kinase (1) Cyclophilin (1) Cytochrome P450 (8) DAPK (1) Deubiquitinase (1) DNA/RNA Synthesis (6) Drug Derivative (10) Drug Intermediate (1) Dynamin (2) E3 Ligase Ligand-Linker Conjugates (1) EAAT (2) Endogenous Metabolite (34) Endoplasmic Reticulum Oxidoreductase 1 (ERO1) (1) Endothelin Receptor (1) Environmental Pollutants (14) Epigenetic Reader Domain (5) ERK (8) Factor Xa (1) FASTK (2) Ferroptosis (15) Fluorescent Dye (1) Formyl Peptide Receptor (FPR) (1) Fungal (3) FXR (1) GABA Receptor (9) Gap Junction Protein (1) GHSR (1) Glutathione Peroxidase (3) Glycine Receptor (GlyR) (1) Glycoprotein VI (1) GSK-3 (2) GSNOR (2) HDAC (2) Heme Oxygenase (HO) (2) HIF/HIF Prolyl-Hydroxylase (18) Histone Acetyltransferase (1) Histone Methyltransferase (1) HIV Integrase (1) HPV (1) HSP (5) iGluR (28) IKK (2) Influenza Virus (1) Insecticide (2) Integrin (7) Interleukin Related (14) IRAK (1) Isotope-Labeled Compounds (23) JAK (1) JNK (3) Keap1-Nrf2 (10) Lactate Dehydrogenase (3) LDLR (1) Leukotriene Receptor (2) Ligands for Target Protein for PROTAC (1) Liposome (7) Lipoxygenase (4) LPL Receptor (1) mAChR (1) MDM-2/p53 (3) mGluR (13) Microsomal Triglyceride Transfer Protein (MTP) (1) Mitochondrial Metabolism (8) Mixed Lineage Kinase (5) MMP (5) MOFs (1) Monoamine Oxidase (3) mTOR (14) Na+/H+ Exchanger (NHE) (3) nAChR (4) NADPH Oxidase (2) Necroptosis (8) NF-κB (28) NO Synthase (16) NOD-like Receptor (NLR) (7) Nuclear Factor of activated T Cells (NFAT) (1) Nucleoside Transporters (3) Opioid Receptor (3) P2X Receptor (4) P2Y Receptor (5) p38 MAPK (8) p97 (1) PARP (4) PDGFR (1) PDK-1 (1) PGC-1α (4) Phosphatase (1) Phosphodiesterase (PDE) (5) Phospholipase (5) PI3K (9) PINK1/Parkin (2) PKA (5) PKC (2) PKG (1) Platelet-activating Factor Receptor (PAFR) (1) Potassium Channel (12) PPAR (1) Prostaglandin Receptor (9) Protease Activated Receptor (PAR) (1) Proteasome (1) Pyroptosis (3) RANKL/RANK (2) RAR/RXR (1) Reactive Oxygen Species (ROS) (30) Reference Standards (36) Renin (1) RIP kinase (6) ROCK (4) SARS-CoV (4) SDCBP (1) Ser/Thr Protease (4) Sigma Receptor (1) Sirtuin (3) Small Interfering RNA (siRNA) (2) Smo (1) SOD (4) Sodium Channel (9) STAT (15) Succinate Dehydrogenase (1) Succinate Receptor 1 (1) TGF-beta/Smad (4) TGF-β Receptor (1) Thrombin (2) Tie (1) TNF Receptor (7) Toll-like Receptor (TLR) (8) TRP Channel (10) Tyrosinase (1) Vasopressin Receptor (1) VEGFR (3) Virus Protease (3)
By Research Areas:	Cancer (58) Cardiovascular Disease (206) Endocrinology (14) Infection (23) Inflammation/Immunology (98) Metabolic Disease (61) Neurological Disease (229)
Oligonucleotides:	Adenosine (1) Pegylated Lipids (5) Nucleoside Analogs (1) Cationic Lipids (2) siRNA drugs (2) Antisense Oligonucleotides (1) siRNAs (2)

372

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P1061

Colivelin Maximum Cited Publications 92 Publications Verification	STAT Amyloid-β	Neurological Disease
Colivelin is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3 in vitro . Colivelin exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease . Colivelin has the potential for the treatment of alzheimer's disease and ischemic brain injury

HY-B0203A

Nebivolol hydrochloride 3 Publications Verification R 065824 hydrochloride	Adrenergic Receptor	Cardiovascular Disease Endocrinology Cancer
Nebivolol (R 065824) hydrochloride is an orally active beta receptor blocker and has the high beta(1)-receptor affinity.Nebivolol hydrochloride has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol hydrochloride can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .

HY-B1614

Clenbuterol hydrochloride 5+ Cited Publications NAB-365 hydrochloride	Adrenergic Receptor	Metabolic Disease Inflammation/Immunology Endocrinology
Clenbuterol (NAB-365) hydrochloride, a selective β2-adrenergic agonist, enhances skeletal muscle strength and hypertrophy. Clenbuterol hydrochloride induces growth factor mRNA, activates astrocytes, and protects rat brain tissue against ischemic damage .

HY-12807

FIPI 5 Publications Verification 5-Fluoro-2-indolyl deschlorohalopemide	Phospholipase	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
FIPI is a phospholipase D (PLD) inhibitor with an IC₅₀ for PLD1 and PLD2 of about 25 nM. FIPI regulates cytoskeletal recombination, cell diffusion and chemotaxis. FIPI can be used in cancer research. In addition, FIPI can enhance the secretion and aggregation of platelet dense particles, inhibit thrombosis, reduce ischemic stroke infarct volume and improve nerve function .

HY-W017540

Cyclocreatine 1 Publications Verification	ATP Synthase	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Cyclocreatine, a creatine analogue, acts as a brain-penetrant and potent bioenergetic protective agent by providing high levels of ATP. Cyclocreatine can be phosphorylated and dephosphorylated by creatine kinases. Cyclocreatine suppresses creatine metabolism ameliorating the cognitive, autistic and epileptic phenotype in a mouse model of creatine transporter defciency. Cyclocreatine protects against ischemic injury and enhances cardiac recovery during early reperfusion in dogs and rats. Cyclocreatine decreases plaque-adjacent neuronal dystrophy in TREM2-deficient mice with amyloid-β pathology. Cyclocreatine is proming for research of ischemic heart disease, cardiovascular diseases, Alzheimer’s disease and other neurodegenerative diseases associated with microglial dysfunction, prostate cancer .

HY-B0203

Nebivolol 3 Publications Verification R 065824	Adrenergic Receptor	Cardiovascular Disease Endocrinology Cancer
Nebivolol (R 065824) is an orally active beta receptor blocker and has the high beta(1)-receptor affinity. Nebivolol has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .

HY-P1061A

Colivelin TFA Maximum Cited Publications 92 Publications Verification	STAT Amyloid-β Apoptosis	Neurological Disease
Colivelin TFA is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3 in vitro . Colivelin TFA exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease . Colivelin TFA has the potential for the treatment of alzheimer's disease and ischemic brain injury .

HY-160186

20-SOLA 1 Publications Verification	Cytochrome P450	Cardiovascular Disease Metabolic Disease Endocrinology
20-SOLA is an orally active 20-HETE antagonist. 20-SOLA greatly ameliorates changes in blood pressure and renal injury associated with a Streptozotocin (STZ) (HY-13753)-diabetic mouse model. 20-SOLA facilitates the restoration of coronary collateral growth (CCG) after ischemic injury. 20-SOLA can be studied for research in cardiovascular diseases and diabetes .

HY-175032

ATF3-IN-1	Ferroptosis Epigenetic Reader Domain Reactive Oxygen Species (ROS) Glutathione Peroxidase	Cardiovascular Disease Neurological Disease
ATF3-IN-1 is a ferroptosis and ATF3 inhibitor. ATF3-IN-1 inhibits oxidative stress and ferroptosis through the ATF3/SLC7A11/GPX4 pathway, exerting anti-ischemic stroke effects. ATF3-IN-1 can attenuate ischemia/reperfusion (I/R) injury and improve neuronal survival. ATF3-IN-1 has neuroprotective effects and can be used to study ischemic stroke .

HY-100957

Dilazep dihydrochloride 2 Publications Verification	Nucleoside Transporters	Cardiovascular Disease
Dilazep dihydrochloride is an inhibitor of adenosine uptake. Dilazep dihydrochloride has cerebral and coronary vasodilating action through enhancement of effect of adenosine. Dilazep dihydrochloride also inhibits the ischemic damage, platelet aggregation, and membrane transport of nucleosides .

HY-P10275

Tat-NTS peptide	Apoptosis	Neurological Disease
Tat-NTS peptide is a cell-penetrating peptide with neuroprotective effects. Tat-NTS peptide can specifically inhibit the nuclear translocation of ANXA1 and reduce neuronal apoptosis in ischemic areas. Moreover, Tat-NTS peptide can reduce the volume of cerebral ischemic infarction and can be used in the research of ischemic stroke .

HY-N0546

Ligustroflavone 2 Publications Verification Nuezhenoside	CaSR RIP kinase Mixed Lineage Kinase TGF-beta/Smad	Cardiovascular Disease Neurological Disease Metabolic Disease Endocrinology
Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the RIPK1/RIPK3/MLKL pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis .

HY-P11117

TAT-EE3	TRP Channel iGluR Calcium Channel	Neurological Disease
TAT-EE3 is a neuroprotective peptide which can uncouple TRPM2-NMDARs interaction. TAT-EE3 inhibits TRPM2-induced enhancement of NMDAR surface expression and current amplitude.TAT-EE3 protects neurons against ischemic injury in vitro and in vivo. TAT-EE3can be used for the study of ischemic stroke .

HY-115460

AER-271 1 Publications Verification	Aquaporin	Cardiovascular Disease Neurological Disease
AER-271, a phosphonate proagent derivative of AER-270, is an aquaporin-4 (AQP4) inhibitor for the research of acute ischemic stroke .

HY-137500

NT1-014B 1 Publications Verification	Liposome Biochemical Assay Reagents	Cardiovascular Disease Neurological Disease
NT1-014B is a tryptamine-derived lipidoid. NT1-014B incorporates NT-lipidoid into BBB-impermeable lipid nanoparticles (LNPs), enabling the LNPs to cross the BBB. NT1-014B enhances brain delivery via intravenous injection. NT1-014B can be used in ischemic stroke research .

HY-173591

T0080	Formyl Peptide Receptor (FPR) Apoptosis	Cardiovascular Disease Neurological Disease Inflammation/Immunology
T0080 is a central nervous system-penetrant FPR1 inhibitor. By functionally blocking the FPR1 signaling pathway, T0080 effectively reduces neutrophil infiltration into ischemic brain tissue and maintains the integrity of the blood-brain barrier. T0080 alleviates tPA-associated hemorrhagic transformation, inhibits demyelination responses and the expression of NOX2. T0080 also possesses anti-apoptotic (apoptosis) and anti-inflammatory properties, thereby protecting myelin and reducing neurological deficits. T0080 is widely used in studies related to ischemic stroke complicated by hemorrhagic transformation after tPA thrombolysis, as well as multiple sclerosis .

HY-138233

KUS121	p97	Neurological Disease Inflammation/Immunology
KUS121, a valosin-containing protein (VCP, p97) modulator with significant neuroprotective effects, attenuates ischemic retinal cell death via suppressing endoplasmic reticulum stress .

HY-109097

Otaplimastat SP-8203	MMP iGluR	Neurological Disease Inflammation/Immunology Cancer
Otaplimastat (SP-8203), a matrix metalloproteinase (MMP) inhibitor, blocks N-methyl-D-aspartate (NMDA) receptor-mediated excitotoxicity in a competitive manner. Otaplimastat also exhibits anti-oxidant activity. Otaplimastat can be used for the research of brain ischemic injury .

HY-164284

LK-2	Sodium Channel	Neurological Disease
LK-2 is an antagonist for ASIC1a with a K_d of 1.9 μM. LK-2 reduces glutamate-induced ASIC1a current-enhancement with an IC₅₀ of 6.6 μM. LK-2 exhibits neuroprotective efficacy in mouse ischemic stroke model, with improved motor and coordination skills. LK-2 is blood-brain barrier (BBB) penetrable .

HY-156757

MDL-811	Sirtuin Interleukin Related Cytochrome P450	Neurological Disease Inflammation/Immunology Cancer
MDL-811 is a selective allosteric activator of SIRT6 with an EC₅₀ of 5.7 μM. MDL-811 possesses anti-inflammatory, antitumor, and neuroprotective activities. MDL-811 can be used for the research of diseases such as colorectal cancer and ischemic stroke .

HY-103346

MMPSI	Caspase Apoptosis	Cardiovascular Disease
MMPSI is a potent and selective small molecule caspase 3 and caspase 7 inhibitor with an IC₅₀ of 1.7 μM for human caspase-3. MMPSI can significantly reduce ischemia-reperfusion-induced infarct size in the isolated rabbit heart, and reduce apoptosis in both the ischemic myocardium and isolated cardiomyocytes. MMPSI can be used for researching cardioprotection .

HY-16637D

Folic acid disodium 20+ Cited Publications Vitamin B9 disodium; Vitamin M disodium	Endogenous Metabolite DNA/RNA Synthesis	Others Neurological Disease Cancer
Folic acid disodium (Vitamin B9 disodium; Vitamin M disodium) is an orally active disodium salt form of Folic acid (HY-16637) with an intrinsic dissolution rate (IDR) of 4.96·10 ⁵ g/s . Folic acid disodium serves as cofactor in single-carbon transfer reactions and exhibits protective effects against neural tube defects, ischemic events, and cancer. Folate acid disodium overload leads to impaired brain development in embryogenesis and promotes growth of precancerous altered cells. Folic acid deficiency leads to megaloblastic anemia .

HY-162359

BIO-7488	IRAK	Neurological Disease Inflammation/Immunology
BIO-7488 is an orally active, selective and blood-brain barrier permeable IRAK4 inhibitor, with an IC₅₀ value of 0.5 nM. BIO-7488 inhibits the production of pro-inflammatory cytokines (IL-1β, TNFα, IL-6) and demonstrates anti-inflammatory effects in both LPS (HY-D1056) and distal hypoxic-middle cerebral artery occlusion (DH-MCAO) ischemic stroke model. BIO-7488 can be used for the study of neuroinflammatory-related diseases, particularly ischemic stroke .

HY-107700

Gavestinel sodium salt GV 150526A	iGluR	Cardiovascular Disease
Gavestinel (GV 150526A) is a potent, selective, orally active and non-competitive antagonist of NMDA receptor. Gavestinel binds to the glycine site of the NMDA receptor, with a pK_i of 8.5. Gavestinel can be used for the research of acute ischemic stroke .

HY-108649A

MRS2768 tetrasodium salt	P2Y Receptor	Cardiovascular Disease
MRS2768 tetrasodium salt is a moderately potent and selective P2Y2 receptor agonist. MRS2768 tetrasodium salt has a protective effect on cardiomyocytes from ischemic damage in vivo and in vitro .

HY-143333

Nrf2 activator-3 1 Publications Verification	Keap1-Nrf2	Neurological Disease Inflammation/Immunology
Nrf2 activator-3 is a potent Nrf2 activator. Nrf2 activator-3 is used for cerebral ischemic injury research .

HY-107335

Aplodan Creatinol O-phosphate; Creatinol phosphate; Creatinolfosfate	Biochemical Assay Reagents	Cardiovascular Disease
Aplodan (Creatinol O-phosphate) is an antiischemic and antiarrhythmic agent. Aplodan has a protective action on cell membrane. Aplodan has the potential for the research of ischemic heart or acute myocardial infarction .

HY-136055

(S,R,S)-AHPC-C5-COOH VH032-C5-COOH	E3 Ligase Ligand-Linker Conjugates HIF/HIF Prolyl-Hydroxylase	Cancer
(S,R,S)-AHPC-C5-COOH (VH032-C5-COOH) is a synthesized E3 ligase ligand-linker conjugate, contains the VH032 VHL-based ligand and a linker to form PROTACs. VH-032 is a selective and potent inhibitor of VHL/HIF-1α interaction with a K_d of 185 nM, has the potential for the study of anemia and ischemic diseases .

HY-P2933

Activated protein C	Factor Xa Protease Activated Receptor (PAR)	Cardiovascular Disease
Activated protein C is an anticoagulant targeting coagulation factors Va and VIIIa. Activated protein C demonstrates cytoprotective effects through binding to endothelial cell protein C receptor (EPCR) and protease-activated receptor-1 (PAR-1), regulating gene expression, anti-inflammation, anti-apoptosis, and stabilizing endothelial barriers. Activated protein C is promising for research of diseases such as severe sepsis and ischemic stroke .

HY-P11048

Thrombin-cleavable peptide	Thrombin	Cardiovascular Disease Neurological Disease
Thrombin-cleavable peptide is a type of peptide that can be recognized and cleaved by thrombin. After cleavage, Thrombin-cleavable peptide releases thrombolytic peptides to initiate thrombolysis. Thrombin-cleavable peptide can be used in the research of diseases such as ischemic stroke .

HY-P11315

MG1 peptide	Biochemical Assay Reagents	Cardiovascular Disease Neurological Disease
MG1 peptide is an M1 microglia-targeting peptide with blood-brain barrier permeability. MG1 peptide can be used in studies related to ischemic stroke and cerebral ischemia-reperfusion injury .

HY-149967

GluN2B-NMDAR antagonist-1	iGluR	Neurological Disease Inflammation/Immunology
GluN2B-NMDAR antagonist-1 is an orally active GluN2B-NMDAR antagonist. GluN2B-NMDAR antagonist-1 has neuroprotective activity. GluN2B-NMDAR antagonist-1 can be used for research of ischemic injury .

HY-175593

M6766	Endoplasmic Reticulum Oxidoreductase 1 (ERO1) Reactive Oxygen Species (ROS)	Cardiovascular Disease Neurological Disease
M6766 is a selective endoplasmic reticulum oxidoreductase 1α (ERO1α) inhibitor with an IC₅₀ of 1.4 μM and a K_D of 1.1 μM. M6766 also inhibits ERO1β with an IC₅₀ of 7.2 μM. M6766 binds to the flavin adenine dinucleotide-binding pocket in ERO1α. M6766 inhibits granule secretion, αIIbβ3 integrin activation, Ca ²⁺ mobilization, and platelet aggregation. M6766 can be used for the research of neurological disease, such as ischemic stroke .

HY-101317

TAN-67 dihydrobromide 1 Publications Verification SB-205607 dihydrobromide	Opioid Receptor	Neurological Disease
TAN-67 (SB-205607) dihydrobromide is a potent and selective nonpeptidic δ-opioid receptor agonist with a K_i value of 0.647 nM. TAN-67 dihydrobromide has neuroprotective effect. TAN-67 dihydrobromide can be used in research of ischemic stroke .

HY-113898

Ganoderic acid K	Angiotensin-converting Enzyme (ACE) Toll-like Receptor (TLR) Interleukin Related	Cardiovascular Disease Neurological Disease
Ganoderic acid K is a triterpenoid compound. Ganoderic acid K can be isolated from Ganoderma lucidum. Ganoderic acid K inhibits ACE activity with an IC₅₀ of 2.6×10 ^-5 M. Ganoderic acid K exhibits direct, high-affinity binding to recombinant MD2 protein, with a K_d value of 0.47 μM. It potently inhibits LPS-induced release of TNF-α and IL-6. It reduces cerebral infarction volume and ameliorates neurological dysfunction in mice with ischemic stroke in the tMCAO model. Ganoderic acid K can be used in studies related to hypertension and ischemic stroke .

HY-153595

DAPK-IN-2	DAPK	Cardiovascular Disease
DAPK-IN-2 is a DAPK inhibitor. DAPK-IN-2 can be used for the research of cerebral infarction and ischemic diseases .

HY-105692

DR2313	PARP	Neurological Disease
DR2313 is a potent, selective, competitive and brain-penetrant inhibitor of poly(ADP-ribose) polymerase (PARP), with IC₅₀s of 0.20 μM and 0.24 μM for PARP-1 and PARP-2, respectively. DR2313 exhibits neuroprotective effects on ischemic injuries in vitro and in vivo .

HY-66010

Cinepazide Maleate MD-67350	Calcium Channel	Cardiovascular Disease
Cinepazide Maleate (MD-67350) is a piperazine derivative and acts as a weak calcium channel blocker. Cinepazide Maleate is a potent vasodilator and can be used for the research of cerebrovascular diseases, including ischemic stroke, brain?infarct et. al .

HY-100957R

Dilazep dihydrochloride (Standard)	Nucleoside Transporters Reference Standards	Cardiovascular Disease
Dilazep (dihydrochloride) (Standard) is the analytical standard of Dilazep (dihydrochloride). This product is intended for research and analytical applications. Dilazep dihydrochloride is an inhibitor of adenosine uptake. Dilazep dihydrochloride has cerebral and coronary vasodilating action through enhancement of effect of adenosine. Dilazep dihydrochloride also inhibits the ischemic damage, platelet aggregation, and membrane transport of nucleosides .

HY-126049

(S)-Oxiracetam (S)-(-)-Oxiracetam; (S)-ISF2522	Apoptosis	Neurological Disease
(S)-oxiracetam (S-ORC) is an inhibitor targeting apoptosis. S-ORC reduces brain infarct size and lessens neurological dysfunction in middle cerebral artery occlusion/reperfusion (MCAO/R) models. S-ORC prevents neuronal apoptosis via activating PI3K/Akt/GSK3β signaling pathway via α7 nAChR after ischemic stroke. S-ORC can prevent neuronal death after ischemic stroke .

HY-172687

DSPE-PEG2000-CSTSMLKAC	Liposome	Cardiovascular Disease
DSPE-PEG2000-CSTSMLKAC is a PEG compound which composed of DSPE and a peptide (CSTSMLKAC). DSPE-PEG2000-CSTSMLKAC can be used for drug delivery DSPE-PEG2000-CSTSMLKAC enables targeted delivery of associated nanoliposomes to ischemic myocardial cells .

HY-19382

EUK-189	SOD ERK Reactive Oxygen Species (ROS)	Neurological Disease
EUK-189 is a synthetic superoxide dismutase (SOD) and catalase mimetic. EUK-189 can block oxygen/glucose deprivation (OGD)-induced ERK1/2 dephosphorylation, ATP depletion and eliminate ROS production. EUK-189 exhibits neuroprotective effect and can inhibit delayed radiation injury. EUK-189 can be used for the research of neurological disease, such as ischemic stroke .

HY-124109

TRC051384 hydrochloride	HSP	Cardiovascular Disease Neurological Disease
TRC051384 hydrochloride is a potent inducer of heat shock protein 70 (HSP70). TRC051384 hydrochloride exhibits protective effects against neuronal trauma via inhibition of necroptosis. TRC051384 hydrochloride can be used for the research of ischemic stroke .

HY-151547

MRS4719	P2X Receptor	Neurological Disease
MRS4719 is a potent P2X4 receptor antagonist with an IC₅₀ value of 0.503 μM for human P2X4 receptor. MRS4719 can reduce infarct volume and reduce brain atrophy, showing neuroprotective and neuro-rehabilitative activities in ischemic stroke model. MRS4719 also reduces ATP-induced [Ca ²⁺]_i influx in primary human monocyte-derived macrophages. MRS4719 can be used to research ischemic stroke .

HY-176275

GSNOR-IN-2	GSNOR	Neurological Disease
GSNOR-IN-2 (Compound 45) is a S-nitrosoglutathione reductase (GSNOR) inhibitor with an IC₅₀ of 44.12 nM. GSNOR-IN-2 has neuroprotective activity, promising for ischemic stroke research .

HY-178393

TRPM2-IN-2	TRP Channel	Neurological Disease Metabolic Disease
TRPM2-IN-2 is a potent and selective TRPM2 inhibitor (IC₅₀ = 0.66 μM) with minimal activity against TRPM8 and TRPV1 (IC₅₀ >10 μM). TRPM2-IN-2 exhibits robust neuroprotective effects in both in vitro oxygen-glucose deprivation/reperfusion (OGD/R) model and in vivo transient middle cerebral artery occlusion (tMCAO) mouse model. TRPM2-IN-2 can be used for ischemic stroke research .

HY-P5754

TAT-NEP1-40	Apoptosis	Neurological Disease
TAT-NEP1-40 is a BBB-penatrable peptide. TAT-NEP1-40 protects PC12 cells against oxygen and glucose deprivation (OGD), and promotes neurite outgrowth. TAT-NEP1-40 also improves ischemia-induced neurologic outcomes by inhibiting cell apoptosis in ischemic brains. TAT-NEP1-40 can be used for research of CNS injuries, such as axonal regeneration and functional recovery after stroke .

HY-123659

KR-33028	Na+/H+ Exchanger (NHE) Apoptosis	Cardiovascular Disease Cancer
KR-33028 is a selective NHE1 inhibitor. KR-33028 reduces hypoxia-induced necrosis and apoptosis in H9c2 cells. KR-33028 inhibits hypoxia-induced increases in cytoplasmic and mitochondrial Ca ²⁺ levels and cytochrome c release. KR-33028 improves cardiac contractility, reduces lactate dehydrogenase release, and increases tissue ATP, creatine phosphate, and glycogen levels. KR-33028 can be used in research on cancers such as cardioblastoma and cardiovascular diseases such as ischemic stroke .

HY-W017540R

Cyclocreatine (Standard)	Reference Standards ATP Synthase	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Cyclocreatine, a creatine analogue, acts as a brain-penetrant and potent bioenergetic protective agent by providing high levels of ATP. Cyclocreatine can be phosphorylated and dephosphorylated by creatine kinases. Cyclocreatine suppresses creatine metabolism ameliorating the cognitive, autistic and epileptic phenotype in a mouse model of creatine transporter defciency. Cyclocreatine protects against ischemic injury and enhances cardiac recovery during early reperfusion in dogs and rats. Cyclocreatine decreases plaque-adjacent neuronal dystrophy in TREM2-deficient mice with amyloid-β pathology. Cyclocreatine is proming for research of ischemic heart disease, cardiovascular diseases, Alzheimer’s disease and other neurodegenerative diseases associated with microglial dysfunction, prostate cancer .

HY-178464

RIPK1-IN-34	RIP kinase Mixed Lineage Kinase Necroptosis	Neurological Disease Inflammation/Immunology
RIPK1-IN-34 is a selective, brain-penetrant RIPK1 inhibitor (IC₅₀ = 126.70 nM) with almost no inhibitory effect on RIPK3 (IC₅₀ ＞ 10, 000 nM). RIPK1-IN-34 offers substantial neuroprotection by inhibiting the phosphorylation of RIPK1, RIPK3, and mixed lineage kinase domain-like pseudokinase (MLKL) within the necroptosis pathway. RIPK1-IN-34 shows the neuroprotective effect in a rat middle cerebral artery occlusion (MCAO) model. RIPK1-IN-34 can be used for the study of anti-acute ischemic stroke (AIS) .

Cat. No.	Product Name

HY-L088

Angiogenesis-Related Compound Library

3,431 compounds

Angiogenesis is the physiological process through which new blood vessels are formed from pre-existing vessels. It occurs in various physiological processes e.g. embryonic development, menstrual cycle, exercise and wound healing etc. Angiogenesis is regulated by both endogenous activators and inhibitors. Some key activators of angiogenesis include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), angiogenin, TGF-β, etc. whereas angiogenesis inhibitors are angiostatin, endostatin, interferon, platelet factor 4, etc. The loss of balance between these opposing signals leads to life threatening diseases like cancer, cardiovascular and ischemic diseases etc. which are thus controlled by exogenous angiogenesis activators (for cardiovascular/ischemic disorders) and inhibitors (for cancer).

MCE offers a unique collection of 3,431 compounds with validated angiogenesis targets modulating properties. MCE angiogenesis-related compound library is an effective tool for angiogenesis research and discovery of angiogenesis-related drugs.

Cat. No.	Product Name	Type

HY-137500

NT1-014B 1 Publications Verification	Biochemical Assay Reagents
NT1-014B is a tryptamine-derived lipidoid. NT1-014B incorporates NT-lipidoid into BBB-impermeable lipid nanoparticles (LNPs), enabling the LNPs to cross the BBB. NT1-014B enhances brain delivery via intravenous injection. NT1-014B can be used in ischemic stroke research .

HY-NP001

Cationic Bovine Serum Albumin

1 Publications Verification

CBSA

Biochemical Assay Reagents

Cationic Bovine Serum Albumin is a bovine serum albumin (BSA) modified with excess ethylenediamine, which has enhanced immunogenicity compared to native BSA. Positively charged primary amines block all negatively charged carboxyl groups, making Cationic Bovine Serum Albumin a cationic protein. Cationic Bovine Serum Albumin has remarkable neuroprotective effects on ischemic stroke when in combination with Tanshinone IIA (HY-N0135) .

HY-172705

DSPE-PEG2000-RVG29

Biochemical Assay Reagents

DSPE-PEG2000-RVG29 is a PEG conjugate composed of DSPE and rabies virus glycoprotein 29 (RVG29). RVG29 specifically binds to nicotinic acetylcholine receptors (nAChR) at the blood-brain barrier (BBB), crosses the BBB, and mediates receptor-dependent transcytosis. DSPE-PEG2000-RVG29 can be used for brain-targeted drug delivery, surface modification of nanocarriers, as well as gene and nucleic acid delivery. DSPE-PEG2000-RVG29 is applicable to research related to hypoxic-ischemic brain injury, Parkinson's disease, and other conditions .

HY-NP192

Sericin

Biochemical Assay Reagents

Sericin is an orally active globular protein produced by silkworm cocoons. Sericin inhibits the expression of COX2, iNOS, TLR4, MAPK and NF-κB; reduces the levels of IL-18, IL-1 and CCL2; antagonizes the activity of AChE; and downregulates the expression of Bcl-2. Sericin enhances the PI3K/AKT-mediated insulin signaling pathway. Sericin inhibits the activity of tyrosinase (Tyrosinase), scavenges ROS, chelates metal ions, and increases the levels of antioxidant enzymes. Sericin induces apoptosis and arrests the cell cycle. Sericin exhibits antibacterial, moisturizing, cardioprotective and anticoagulant properties. Sericin can be used in research related to type 2 diabetes, hyperlipidemia, obesity, Alzheimer's disease, colon cancer, peripheral nerve injury and ischemic myocardial infarction .

HY-W329357

15:0 Lyso PC

1 Publications Verification

Biochemical Assay Reagents

15:0 Lyso PC is a lysophosphatidylcholine (Lyso PC), a product of phospholipase A2 (PLA2) hydrolysis of phosphatidylcholine (PC) and is involved in cell membrane remodeling and inflammatory signaling. 15:0 Lyso PC demonstrates significant lipid metabolism disturbances in the serum with ischemic heart disease (IHD) and ischemic cardiomyopathy (ICM). 15:0 Lyso PC can be used as a lipid biomarker for cardiovascular disease .

HY-W795960

D-myo-Inositol 1,4,5-trisphosphate sodium salt

Biochemical Assay Reagents

D-myo-inositol 1,4,5-trisphosphate sodium salt is a widely distributed intracellular second messenger. D-myo-inositol 1,4,5-trisphosphate sodium salt acts as a potent agonist of the Ins (1,4,5) P₃ receptor with an EC₅₀ of 0.12 μM and inhibits bovine PLC-δ1, with an IC₅₀ of 5.4 μM for binding and an IC₅₀ of 12.4 μM for hydrolysis. D-myo-inositol 1,4,5-trisphosphate sodium saltis metabolized into Ins (1,4) P₂ and Ins (1,3,4,5) P₄. D-myo-inositol 1,4,5-trisphosphate sodium salt mediates various cellular processes, including growth, development, fertilization, secretion, contraction and neuromodulation. D-myo-inositol 1,4,5-trisphosphate sodium salt inhibits PIP₂ hydrolysis and Ca ²⁺-ATPase activity. D-myo-inositol 1,4,5-trisphosphate sodium salt is used for cardiac preconditioning, exerts cardioprotective effects and mimics ischemic preconditioning. D-myo-inositol 1,4,5-trisphosphate sodium salt is applied in studies related to intracellular calcium and phosphoinositol signaling pathways .

HY-172687

DSPE-PEG2000-CSTSMLKAC	Biochemical Assay Reagents
DSPE-PEG2000-CSTSMLKAC is a PEG compound which composed of DSPE and a peptide (CSTSMLKAC). DSPE-PEG2000-CSTSMLKAC can be used for drug delivery DSPE-PEG2000-CSTSMLKAC enables targeted delivery of associated nanoliposomes to ischemic myocardial cells .

HY-172687A

DSPE-PEG3400-CSTSMLKAC	Biochemical Assay Reagents
DSPE-PEG3400-CSTSMLKAC is a PEG compound which composed of DSPE and a peptide (CSTSMLKAC). CSTSMLKAC is capable of mediating selective homing of phage to ischemic heart tissue. DSPE-PEG3400-CSTSMLKAC can be used for drug delivery .

HY-172688

DSPE-PEG5000-CSTSMLKAC	Biochemical Assay Reagents
DSPE-PEG5000-CSTSMLKAC is a PEG compound which composed of DSPE and a peptide (CSTSMLKAC). CSTSMLKAC is capable of mediating selective homing of phage to ischemic heart tissue. DSPE-PEG5000-CSTSMLKAC can be used for drug delivery .

HY-172705A

DSPE-PEG3400-RVG29

Biochemical Assay Reagents

DSPE-PEG3400-RVG29 is a PEG conjugate composed of DSPE and rabies virus glycoprotein 29 (RVG29). RVG29 specifically binds to nicotinic acetylcholine receptors (nAChR) at the blood-brain barrier (BBB), crosses the BBB, and mediates receptor-dependent transcytosis. DSPE-PEG3400-RVG29 can be used for brain-targeted drug delivery, surface modification of nanocarriers, as well as gene and nucleic acid delivery. DSPE-PEG3400-RVG29 is applicable to research related to hypoxic-ischemic brain injury, Parkinson's disease, and other conditions

HY-172686

DSPE-PEG1000-CSTSMLKAC	Biochemical Assay Reagents
DSPE-PEG1000-CSTSMLKAC is a PEG compound which composed of DSPE and a peptide (CSTSMLKAC). CSTSMLKAC is capable of mediating selective homing of phage to ischemic heart tissue. DSPE-PEG1000-CSTSMLKAC can be used for drug delivery .

Cat. No.	Product Name	Target	Research Area

HY-P1061

Colivelin Maximum Cited Publications 92 Publications Verification	STAT Amyloid-β	Neurological Disease
Colivelin is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3 in vitro . Colivelin exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease . Colivelin has the potential for the treatment of alzheimer's disease and ischemic brain injury

HY-P1061A

Colivelin TFA Maximum Cited Publications 92 Publications Verification	STAT Amyloid-β Apoptosis	Neurological Disease
Colivelin TFA is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3 in vitro . Colivelin TFA exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease . Colivelin TFA has the potential for the treatment of alzheimer's disease and ischemic brain injury .

HY-113110

Cysteinylglycine L-Cysteinylglycine; Cys-Gly; H-Cys-Gly-OH	Endogenous Metabolite Reactive Oxygen Species (ROS) DNA/RNA Synthesis	Cardiovascular Disease Cancer
Cysteinylglycine (L-Cysteinylglycine; Cys-Gly) is a dipeptide formed by the peptide bond linkage between cysteine (Cysteine) and glycine (Glycine). Cysteinylglycine is an important metabolic intermediate in the human body, mainly derived from the degradation of glutathione (GSH). Cysteinylglycine reduces ferric iron to ferrous iron, drives the redox cycle of iron, generates reactive oxygen species (ROS), stimulates oxidative reactions, induces lipid peroxidation of human plasma LDL lipoproteins, and causes oxidative damage to DNA bases. Cysteinylglycine can be used as a biomarker to evaluate ischemic heart disease, breast cancer and other conditions .

HY-148195

Ercanetide NNZ-2591	Biochemical Assay Reagents	Neurological Disease
Ercanetide (NNZ 2591) is a synthetic analogue of a small peptide of cyclic glycine proline (cGP). Ercanetide shows orally active and cross the blood-brain barrier. Ercanetide shows neuroprotective after ischemic brain injury. NNZ 2591 improves motor function in a rat model of Parkinson's disease. Ercanetide has the potential for the research of ischemic brain injury and angelman syndrome .

HY-P10275

Tat-NTS peptide	Apoptosis	Neurological Disease
Tat-NTS peptide is a cell-penetrating peptide with neuroprotective effects. Tat-NTS peptide can specifically inhibit the nuclear translocation of ANXA1 and reduce neuronal apoptosis in ischemic areas. Moreover, Tat-NTS peptide can reduce the volume of cerebral ischemic infarction and can be used in the research of ischemic stroke .

HY-P10638

TAT-CN21	CaMK	Cardiovascular Disease Neurological Disease
TAT-CN21 is a potent CaMKII inhibitor with an IC₅₀ of 77.2 nM. TAT-CN21 inhibits both calcium/calmodulin-dependent and autonomously activated CaMKII, blocks glutamate-induced translocation of CaMK IIα, and reverses the enhanced phosphorylation of CaMKII at Thr286 following excitotoxic injury. TAT-CN21 shows application potential in studies related to ischemic stroke by reducing neuronal excitotoxicity and exacerbating pre-existing long-term neuronal death prior to injury. TAT-CN21 improves definitive behaviors in rats with residual nerve injury without altering indicators such as mechanical/thermal hyperalgesia or spatial memory. TAT-CN21 can also be used in studies related to neuropathic pain .

HY-P11117

TAT-EE3	TRP Channel iGluR Calcium Channel	Neurological Disease
TAT-EE3 is a neuroprotective peptide which can uncouple TRPM2-NMDARs interaction. TAT-EE3 inhibits TRPM2-induced enhancement of NMDAR surface expression and current amplitude.TAT-EE3 protects neurons against ischemic injury in vitro and in vivo. TAT-EE3can be used for the study of ischemic stroke .

HY-P5883

TAT-M2NX tatM2NX	TRP Channel	Cardiovascular Disease Neurological Disease
TAT-M2NX (tatM2NX) is a selective inhibitor targeting human TRPM2 channels and exerts inhibitory effects on ischemic stroke. TAT-M2NX reduces H₂O₂-induced calcium influx via TRPM2 channels. After traumatic brain injury in mice, TAT-M2NX preserves hippocampal long-term potentiation, improves memory function, and reduces infarct volume after middle cerebral artery occlusion, but it shows no effect on female mice. TAT-M2NX can be used in studies related to traumatic brain injury and ischemic stroke .

HY-P2159

Dynorphin A (1-8)	Opioid Receptor Endogenous Metabolite	Neurological Disease
Dynorphin A (1-8) is a ligand with preference for the κ-opioid receptor, and its IC₅₀ value against human placental κ-opioid receptor is 330 nM. Dynorphin A (1-8) mediates neuroprotective effects by inhibiting oxidative stress, suppressing apoptosis, and competitively displacing the binding of κ partial agonists. Dynorphin A (1-8) is the dominant opioid peptide in human placental villi and tissue extracts; it undergoes rapid hydrolysis and can enter the central nervous system via intranasal administration. Dynorphin A (1-8) can be used in studies related to ischemic stroke .

HY-P3304

MR 409	GHSR	Neurological Disease Cancer
MR 409 is a selected growth hormone-releasing hormone (GHRH) agonist. MR 409 has remarkable neuroprotective effects through enhancing endogenous neurogenesis in cerebral ischemic mice. MR 409 also inhibits the in vivo growth of lung cancer .

HY-P6437A

Drp1 peptide inhibitor P110 TFA	Dynamin	Cardiovascular Disease Neurological Disease
Drp1 peptide inhibitor P110 (Compound P110) TFA is a selective Drp1 peptide inhibitor with neuroprotective properties. Drp1 peptide inhibitor P110 TFA can inhibit the activation of Drp1, prevent MPTP (HY-15608)-induced Drp1 mitochondrial translocation, and alleviate MPTP-induced dopaminergic neuron loss, dopaminergic nerve terminal damage, and behavioral deficits, and can be used in the study of Alzheimer's disease. Additionally, Drp1 peptide inhibitor P110 TFA can reduce mitochondrial damage and organ injury in animal models of Huntington's disease, cerebral ischemic injury, and myocardial infarction .

HY-P5217

CSTSMLKAC (disulfide)	Peptides	Others
CSTSMLKAC (peptide 2) is a cyclic 9 amino acid sequence that mimics endogenous peptide sequences. CSTSMLKAC homes to cardiomyocytes in the ischemic myocardium .

HY-P3369

Gersizangitide AXT-107	VEGFR Tie Akt	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Gersizangitide (AXT107) is an anti-angiogenic peptide consisting of 20 amino acids, derived from collagen IV. Gersizangitide is an inhibitor of VEGF-A and VEGF-C and an activator of Tie2. Gersizangitide can block VEGF receptor signaling, inhibit vascular leakage, neovascularization and inflammation. Gersizangitide can be used in the research of diseases related to ocular neovascularization and angiogenesis .

HY-P2259

TAT-GluA2 3Y 2 Publications Verification	iGluR HIV Integrase Adenosine Receptor	Cardiovascular Disease Neurological Disease
TAT-GluA2 3Y is a blood-brain barrier-permeable AMPA receptor inhibitory peptide that crosses cell membranes via the HIV-1 TAT protein domain. TAT-GluA2 3Y blocks the endocytosis of AMPA receptors, including the internalization of GluA1/GluA2 subunits, by disrupting interactions with the AP2, Brag2 and Syt3-GluA2 complexes, while also inhibiting long-term depression. TAT-GluA2 3Y blocks hypoxia-mediated AMPAR internalization, alleviates A1R-induced persistent synaptic inhibition, and reduces cerebral ischemic volume, neurological deficits and spatial memory deficits. TAT-GluA2 3Y blocks the effect of NLRP3 deficiency on fear generalization, inhibits amphetamine-induced behavioral/neurochemical sensitization, weakens the unconditioned stimulus-conditioned stimulus association of morphine, and promotes the extinction of morphine CPP. TAT-GluA2 3Y can be used in studies related to fear generalization, ischemic stroke, hypoxia, drug addiction and opioid addiction .

HY-P6437

Drp1 peptide inhibitor P110	Dynamin	Cardiovascular Disease Neurological Disease
Drp1 peptide inhibitor P110 (Compound P110) is a selective Drp1 peptide inhibitor with neuroprotective properties. Drp1 peptide inhibitor P110 can inhibit the activation of Drp1, prevent MPTP-induced Drp1 mitochondrial translocation, and alleviate MPTP-induced dopaminergic neuron loss, dopaminergic nerve terminal damage, and behavioral deficits, and can be used in the study of Alzheimer's disease. Additionally, Drp1 peptide inhibitor P110 can reduce mitochondrial damage and organ injury in animal models of Huntington's disease, cerebral ischemic injury, and myocardial infarction .

HY-P5345

KLA peptide	Apoptosis Antibiotic Caspase Mitochondrial Metabolism	Cardiovascular Disease Infection Neurological Disease Metabolic Disease
KLA peptide is a naturally occurring Antibiotic peptide that is nontoxic outside of cells but is toxic when it enters into the interior of targeted cells. KLA peptide can induce cell Apoptosis by disrupting mitochondrial membranes and activating Caspase. MG1-KLA, formed by the coupling of KLA peptide with MG1, can selectively induce apoptosis in pro-inflammatory microglia. KLA peptide can be used for the research of liver fibrosis. KLA peptide can be used for the research of neonatal hypoxic-ischemic encephalopathy.

HY-P5142

ω-Hexatoxin-Hv1a ω-ACTX-Hv1; ω-Atracotoxin-HV1	Insecticide Calcium Channel Apoptosis Necroptosis	Cardiovascular Disease Neurological Disease Inflammation/Immunology
ω-Hexatoxin-Hv1a (ω-ACTX-Hv1; ω-Atracotoxin-HV1) is an orally active insecticidal neurotoxin containing an inhibitor cystine knot motif and a selective calcium channel inhibitor. ω-Hexatoxin-Hv1a blocks L-type voltage-dependent Ca ²⁺ channels and reduces intracellular calcium ion concentration, thereby decreasing apoptosis, necroptosis and oxidative stress, and promoting cell recovery and energy level elevation. ω-Hexatoxin-Hv1a causes larval paralysis and death by impairing neurotransmission in the central nervous system of insects. It shows high injectable toxicity against insects of multiple orders, but exhibits weak oral toxicity. ω-Hexatoxin-Hv1a is widely applicable to studies related to ischemia-reperfusion injury, atopic dermatitis, and ischemic injury of cardiomyocytes and neurons .

HY-P11048

Thrombin-cleavable peptide	Thrombin	Cardiovascular Disease Neurological Disease
Thrombin-cleavable peptide is a type of peptide that can be recognized and cleaved by thrombin. After cleavage, Thrombin-cleavable peptide releases thrombolytic peptides to initiate thrombolysis. Thrombin-cleavable peptide can be used in the research of diseases such as ischemic stroke .

HY-P11315

MG1 peptide	Biochemical Assay Reagents	Cardiovascular Disease Neurological Disease
MG1 peptide is an M1 microglia-targeting peptide with blood-brain barrier permeability. MG1 peptide can be used in studies related to ischemic stroke and cerebral ischemia-reperfusion injury .

HY-P5118A

Tat-peptide 190-208 TFA	Peptides	Neurological Disease
Tat-peptide 190-208 TFA is a cell-permeable and Tat-labeled fusion peptide, corresponding to residues 190-208 of rat G3BP1. Tat sequence from HIV, is placed at the least conserved end of the sequence, for cell permeability. Tat-peptide 190-208 TFA increases axon growth and increases the number of neurites per neuron. Tat-peptide 190-208 TFA likely exhibits an axon intrinsic mechanism. Tat-peptide 190-208 TFA can be used for ischemic protection during endovascular repair for intracranial aneurysms .

HY-113110A

Cysteinylglycine TFA L-Cysteinylglycine TFA; Cys-Gly TFA; H-Cys-Gly-OH TFA	Endogenous Metabolite Reactive Oxygen Species (ROS) DNA/RNA Synthesis	Cardiovascular Disease Cancer
Cysteinylglycine (L-Cysteinylglycine; Cys-Gly) TFA is a dipeptide formed by the peptide bond connection of cysteine and glycine. Cysteinylglycine TFA is an important metabolic intermediate in the human body, mainly derived from the degradation of glutathione (GSH). Cysteinylglycine TFA can reduce trivalent iron to divalent iron, driving the redox cycle of iron, generating reactive oxygen species (ROS), stimulating oxidative reactions, inducing lipid peroxidation in human plasma LDL lipoproteins, and causing oxidative damage to DNA base. Cysteinylglycine TFA can be used as a biomarker to assess ischemic heart disease and breast cancer, etc ^[1][2][3][4].

HY-P11049

Stroke-homing peptide	Peptides	Neurological Disease
Stroke-homing peptide is a homing peptide. Stroke-homing peptide can home to ischemic stroke brain tissue and detect the apoptotic neuronal cells. Stroke-homing peptide can be used for the research of molecular imaging and selective drug delivery to stroke tissue .

HY-P5754

TAT-NEP1-40	Apoptosis	Neurological Disease
TAT-NEP1-40 is a BBB-penatrable peptide. TAT-NEP1-40 protects PC12 cells against oxygen and glucose deprivation (OGD), and promotes neurite outgrowth. TAT-NEP1-40 also improves ischemia-induced neurologic outcomes by inhibiting cell apoptosis in ischemic brains. TAT-NEP1-40 can be used for research of CNS injuries, such as axonal regeneration and functional recovery after stroke .

HY-P11314

ABri	Amyloid-β	Cardiovascular Disease Neurological Disease
ABri, 34 amino acids long, is an Amyloid subunit with certain degree of N- and C-terminal heterogeneity and no sequence identity to any known amyloid protein. ABri is devoid of glycine, methionine, proline, aspartic acid, tryptophane, tyrosine and glutamine, featuring pyroglutamate at its N-terminus. ABri can be used for cerebral hemorrhages, ischemic infarction and Alzheimer disease research .

HY-P10977

Tat-ASIC1a (1-20) (mouse, rat)	Sodium Channel RIP kinase	Neurological Disease
Tat-ASIC1a (1-20) (mouse, rat) is a competitive ASIC1a membrane-penetrating peptide. Tat-ASIC1a (1-20) (mouse, rat) has significantly neuroprotection effects, and reduces neuronal damage against acidotoxicity by targeting the ASIC1a-RIPK1 pathway and auto-inhibitory mechanism. Tat-ASIC1a (1-20) (mouse, rat) effectively protects brains from ischemic injury in ischemic stroke mice model. Tat-ASIC1a (1-20) (mouse, rat) can be used for neurodegenerative diseases research, such as Huntington disease and Parkinson’s disease .

HY-P5754A

TAT-NEP1-40 TFA	Apoptosis	Neurological Disease
TAT-NEP1-40 TFA is a BBB-penatrable peptide. TAT-NEP1-40 TFA protects PC12 cells against oxygen and glucose deprivation (OGD), and promotes neurite outgrowth. TAT-NEP1-40 TFA also improves ischemia-induced neurologic outcomes by inhibiting cell apoptosis in ischemic brains. TAT-NEP1-40 TFA can be used for research of CNS injuries, such as axonal regeneration and functional recovery after stroke .

HY-P5117

TAT-CIRP	Toll-like Receptor (TLR)	Neurological Disease
TAT-CIRP is a a small peptide, refers to Trans-trans-activating (Tat)-cold-inducible RNA binding protein. TAT-CIRP is an inhibitor of myeloid differentiation protein 2 (MD2). TAT-CIRP exhibits robust neuroprotection against ischemic and hemorrhagic stroke in mice .

HY-P5118

Tat-peptide 190-208	Peptides	Neurological Disease
Tat-peptide 190-208 is a cell-permeable and Tat-labeled fusion peptide, corresponding to residues 190-208 of rat G3BP1. Tat sequence from HIV, is placed at the least conserved end of the sequence, for cell permeability. Tat-peptide 190-208 increases axon growth and increases the number of neurites per neuron. Tat-peptide 190-208 likely exhibits an axon intrinsic mechanism. Tat-peptide 190-208 can be used for ischemic protection during endovascular repair for intracranial aneurysms .

HY-P2060

CGP 44099	Renin	Cardiovascular Disease
CGP 44099 is a renin inhibitor. CGP 44099 can be used to study the ischemic injury and reperfusion arrhythmias in rat hearts .

HY-P2281

Atrial natriuretic factor (1-28) (human, porcine) Atrial natriuretic peptide (1-28)	Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
Atrial natriuretic factor (1-28) (human, porcine) exhibits blood pressure lowering activity by increasing sodium and urine excretion. Atrial natriuretic factor (1-28) (human, porcine) inhibits the release of pituitary adrenocorticotropic hormone (ACTH) and beta-endorphin through inhibition of pro-opiomelanocortin (POMC) expression. Atrial natriuretic factor (1-28) (human, porcine) increases cGMP levels in RMIC cells with an IC₅₀ of 1.2 nM .

HY-P5119

Tat-peptide control 168-189	Peptides	Neurological Disease
Tat-peptide 168-189 is a cell-permeable and Tat-labeled fusion peptide, corresponding to residues 168-189 of rat G3BP1. Tat sequence from HIV, is placed at the least conserved end of the sequence, for cell permeability. Tat-peptide 168-189 is the negtive control of Tat-peptide 190-208 (HY-P5118), as Tat-peptide 190-208 increases axon growth and increases the number of neurites per neuron .

HY-175824

PSD-95/nNOS PPI-IN-1	iGluR NO Synthase Apoptosis Reactive Oxygen Species (ROS)	Neurological Disease
PSD-95/nNOS PPI-IN-1 is a inhibitor targeting the PSD-95/nNOS interaction with potential blood-brain barrier penetration. PSD-95/nNOS PPI-IN-1 binds to the PSD-95 PDZ2 domain with high affinity (K_i = 19.45 μM). PSD-95/nNOS PPI-IN-1 inhibits glutamate-induced excitotoxicity by reducing intracellular ROS levels and inhibiting apoptosis. PSD-95/nNOS PPI-IN-1 significantly reduces cerebral infarct volume in rat tMCAO models. PSD-95/nNOS PPI-IN-1 can be used for the study of acute ischemic stroke .

HY-P11777

AG73	MMP SDCBP	Cardiovascular Disease Neurological Disease Cancer
AG73 is a polypeptide. AG73 is derived from the G domain of the Laminin α1 chain. AG73 binds heparin, Syndecan-1 and Syndecan-4. AG73 promotes the adhesion of various cells, induces the differentiation of salivary gland acinar cells, stimulates neurite outgrowth, secretion of matrix metalloproteinases and angiogenesis. AG73 retains its angiogenic activity when conjugated to chitosan membranes. AG73 can be used in the research of melanoma and ischemic injury .

HY-P11210

A68828	Biochemical Assay Reagents	Inflammation/Immunology
A68828 is an atrial natriuretic factor (ANF) analog. A68828 can improve renal function in an acute model of postischemic acute renal failure. A68828 can be studied in research on ischemic acute renal failure .

HY-P5345A

KLA peptide acetate	Apoptosis Antibiotic Caspase Mitochondrial Metabolism	Cardiovascular Disease Infection Neurological Disease Metabolic Disease
KLA peptide acetate is a naturally occurring Antibiotic peptide that is nontoxic outside of cells but is toxic when it enters into the interior of targeted cells. KLA peptide acetate can induce cell Apoptosis by disrupting mitochondrial membranes and activating Caspase. MG1-KLA acetate, formed by the coupling of KLA peptide acetate with MG1, can selectively induce apoptosis in pro-inflammatory microglia. KLA peptide acetate can be used for the research of liver fibrosis. KLA peptide acetate can be used for the research of neonatal hypoxic-ischemic encephalopathy .

HY-P5119A

Tat-peptide control 168-189 TFA	Peptides	Neurological Disease
Tat-peptide 168-189 is a cell-permeable and Tat-labeled fusion peptide, corresponding to residues 168-189 of rat G3BP1. Tat sequence from HIV, is placed at the least conserved end of the sequence, for cell permeability. Tat-peptide 168-189 is the negtive control of Tat-peptide 168-189 TFA (HY-P5118A), as Tat-peptide 168-189 TFA increases axon growth and increases the number of neurites per neuron .

HY-P5142A

ω-Hexatoxin-Hv1a TFA ω-ACTX-Hv1 TFA; ω-Atracotoxin-HV1 TFA	Insecticide Apoptosis Calcium Channel Necroptosis	Cardiovascular Disease Neurological Disease Inflammation/Immunology
ω-Hexatoxin-Hv1a (ω-ACTX-Hv1; ω-Atracotoxin-HV1) TFA is an orally active insecticidal neurotoxin containing an inhibitor cystine knot motif and a selective calcium channel inhibitor. ω-Hexatoxin-Hv1a TFA blocks L-type voltage-dependent Ca ²⁺ channels and reduces intracellular calcium ion concentration, thereby decreasing apoptosis, necroptosis and oxidative stress, and promoting cell recovery and energy level elevation. ω-Hexatoxin-Hv1a TFA causes larval paralysis and death by impairing neurotransmission in the central nervous system of insects. It shows high injectable toxicity against insects of multiple orders, but exhibits weak oral toxicity. ω-Hexatoxin-Hv1a TFA is widely applicable to studies related to ischemia-reperfusion injury, atopic dermatitis, and ischemic injury of cardiomyocytes and neurons .

Cat. No.	Product Name	Target	Research Area	Image

HY-108841

Raleukin 50+ Cited Publications Kineret; Anakinra	Interleukin Related	Inflammation/Immunology Cancer
Raleukin (AMG-719) is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Raleukin significantly reduces neutrophil accumulation in blood vessels and brain infarct volume as well as improves motor coordination performance in ischemic stroke mice model. Anakinra can be used to study chronic inflammatory disorders like rheumatoid arthritis and cardiovascular recurrence post-myocardial infarction .

HY-P99644

ACT017 1 Publications Verification	Glycoprotein VI	Cardiovascular Disease
ACT017 is a Fab fragment of humanized anti-GPVI monoclonal antibody. ACT017 inhibits collagen-induced platelet aggregation. ACT017 has the potential for the research of acute ischemic stroke .

HY-P991604

MLN2201 YFC51.1; LDP-01	Integrin	Inflammation/Immunology
MLN2201 is a humanized monoclonal antibody inhibitor, targeting Integrin β2. MLN2201 inhibits the reperfusion injury after stroke and can be used for inflammatory diseases like ischemic stroke research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0378

D-Mannitol 10+ Cited Publications Mannitol; Mannite	Structural Classification Natural Products other families Classification of Application Fields Metabolic Disease Plants Endogenous metabolite Disease Research Fields Sweeteners Source Classification Food Research	Environmental Pollutants Endogenous Metabolite Apoptosis PGC-1α PKA Adrenergic Receptor
D-Mannitol (Mannitol) is an oral, resistant sugar widely used in the food and pharmaceutical industries to promote the absorption and retention of calcium and magnesium through cecal fermentation, while acting as a osmotic diuretic to reduce tissue edema. D-Mannitol can enhance brown fat formation, improve insulin effect, reduce blood sugar levels, And through the start the β₃-adrenergic receptor (β₃-AR), PGC1α and PKA induced by means of white fat cells into brown fat cells . D-Mannitol is commonly used to maintain osmotic pressure between the plant cytoplasm and the culture medium and protect cells when the cell wall is weakened or even removed .

HY-110281

Dehydroascorbic acid	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Endogenous Metabolite
Dehydroascorbic acid is an oxidized form of vitamin C that can cross the blood-brain barrier (BBB). Dehydroascorbic acid clears cytotoxic reactive oxygen species (ROS) produced after ischemic stroke by converting to ascorbic acid (AA), thereby reducing neuronal and glial cell damage and stabilizing cerebral microvascular NO signaling to maintain perfusion in the ischemic area. Dehydroascorbic acid can be used in research on ischemic stroke .

HY-N0890

Tubeimoside I 4 Publications Verification Tubeimoside-1; Lobatoside-H	Triterpenes Classification of Application Fields Terpenoids Cucurbitaceae Plants Bolbostemma paniculaum (Maxim)Franguet Disease Research Fields Source Classification Cancer	HSP NF-κB p38 MAPK Akt Autophagy Interleukin Related VEGFR
Tubeimoside I is an orally active HSPD1 inhibitor. Tubeimoside I inhibits NF-κB, MAPK, as well as regulates eNOS-VEGF. Tubeimoside I induces cytoprotective Autophagy via an Akt-mediated pathway. Tubeimoside I inhibits proinflammatory cytokine (IL-6 and IL-1β) production. Tubeimoside I exhibits anti-inflammatory activities. Tubeimoside I promotes angiogenesis and improves sepsis symptoms. Tubeimoside I is used in the research of inflammatory diseases, various cancers, sepsis and ischemic diseases .

HY-B1614

Clenbuterol hydrochloride 5+ Cited Publications NAB-365 hydrochloride	Structural Classification Natural Products Classification of Application Fields Endogenous metabolite Inflammation/Immunology Disease Research Fields Endocrinology Source Classification	Adrenergic Receptor
Clenbuterol (NAB-365) hydrochloride, a selective β2-adrenergic agonist, enhances skeletal muscle strength and hypertrophy. Clenbuterol hydrochloride induces growth factor mRNA, activates astrocytes, and protects rat brain tissue against ischemic damage .

HY-113329

Guanidinoethyl sulfonate 5 Publications Verification Taurocyamine	Natural Products Other disease Classification of Application Fields Disease markers Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Guanidinoethyl sulfonate (Taurocyamine) is an orally available, blood-brain permeable competitive inhibitor of taurine transporters and a competitive antagonist of glycine receptors (GlyR) (IC₅₀=565 μM). Guanidinoethyl sulfonate has both weak agonist and antagonist effects on GABA_A receptors. Guanidinoethyl sulfonate inhibits taurine transmembrane transport and competitively binds to the GlyR ligand binding domain, thereby blocking glycine-mediated chloride influx, and may regulate brain pH to exert neuroprotective effects. Guanidinoethyl sulfonate can be used for neuroprotection studies of ischemic brain injury .

HY-106950A

Fosfructose trisodium Diphosphofructose trisodium; Esafosfan trisodium; FDP trisodium	Cardiovascular Disease Structural Classification Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Fosfructose trisodium (Diphosphofructose trisodium, Esafosfan trisodium, FDP trisodium) is a cytoprotective natural sugar phosphate used in research on cardiovascular ischemia, sickle cell anemia, and asthma. Fosfructose trisodium acts by stimulating anaerobic glycolysis, which produces adenosine triphosphate under ischemic conditions .

HY-B0762

Acetyl-L-carnitine hydrochloride 2 Publications Verification O-Acetyl-L-carnitine hydrochloride; ALCAR hydrochloride	Alkaloids Structural Classification Other Alkaloids Endogenous metabolite Source Classification	Caspase Apoptosis
Acetyl-L-carnitine (O-Acetyl-L-carnitine; ALCAR) hydrochloride is an orally active mitochondrial energy metabolism regulator and neuroprotectant that can penetrate the blood-brain barrier. Acetyl-L-carnitine hydrochloride selectively enters cells and the brain through the organic cation transporter OCTN2. Acetyl-L-carnitine hydrochloride can participate in fatty acid β-oxidation, promote acetylcholine synthesis, regulate mitochondrial function and inhibit oxidative stress as an acetyl donor. Acetyl-L-carnitine hydrochloride exerts its activity by enhancing energy metabolism, protecting neurons and improving synaptic plasticity. Acetyl-L-carnitine hydrochloride is mainly used in the study of neurodegenerative diseases and metabolic disorder-related diseases such as neonatal hypoxic-ischemic brain damage, Alzheimer's disease, and depression .

HY-30004

1-Aminocyclopropane-1-carboxylic acid	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Environmental Pollutants Endogenous Metabolite
1-Aminocyclopropane-1-carboxylic acid is an endogenous metabolite. In the presence of low concentrations (1 μM) of glutamate, 1-Aminocyclopropane-1-carboxylic acid acts as a small molecule agonist of NMDA receptors with an EC50 of 0.7-0.9 μM. At high concentrations (10 μM) of glutamate, 1-Aminocyclopropane-1-carboxylic acid acts as a competitive antagonist of NMDA receptors with an EC50 of 81.6 nM. 1-Aminocyclopropane-1-carboxylic acid exerts neuroprotective activity by moderately activating NMDA receptors to prevent neuronal cell death in ischemic animal models. Additionally, 1-Aminocyclopropane-1-carboxylic acid is an antagonist of NMDA receptors, inducing blood pressure reduction and antioxidant effects in stroke-prone hypertensive rats. 1-Aminocyclopropane-1-carboxylic acid enhances object recognition memory and cognitive flexibility dependent on the prefrontal cortex, but does not affect impulsivity nor exhibit an antipsychotic-like profile. 1-Aminocyclopropane-1-carboxylic acid shows promise for research in the field of neurotoxicity. .

HY-N0559

Kirenol 1 Publications Verification	Structural Classification Terpenoids Bituminaria morisiana (Pignatti & Metlesics) Greuter Diterpenoids Plants Compositae Source Classification	Casein Kinase Apoptosis AMPK Akt NF-κB TGF-beta/Smad
Kirenol is a diterpenoid compound, an orally active apoptosis inducer and signaling pathway regulator, with a K_d value of 5.47 μM against the target CK2. Kirenol promotes the cleavage of Bid into tBid, regulates the protein levels/phosphorylation of Bax, Bcl-2, p53 and p21, and induces caspase-independent apoptosis, S-phase cell cycle arrest, ROS accumulation and cytotoxicity in cancer cells. Kirenol activates the CK2/AKT and AMPK-mTOR-ULK1 pathways, inhibits the signaling of NF-κB, TGF-β/Smads and NLRP3 inflammasome, and regulates the GSK3β, BMP and Wnt/β-catenin pathways. Kirenol induces autophagy, mitophagy and osteoblast differentiation, promotes mitochondrial fusion, and exerts antioxidant, anti-inflammatory, antifibrotic, renoprotective, cardioprotective, neuroprotective and analgesic effects. Kirenol is applicable to research related to chronic myeloid leukemia, ischemic stroke, diabetic nephropathy, heart failure, acute lung injury and osteoporosis .

HY-N0361

Dihydrocapsaicin 4 Publications Verification	Alkaloids Structural Classification Monophenols Capsicum annuum L. Classification of Application Fields Other Alkaloids Phenols Metabolic Disease Solanaceae Plants Disease Research Fields Source Classification	Environmental Pollutants Caspase Akt Apoptosis Reactive Oxygen Species (ROS) TRP Channel Bcl-2 Family PI3K
Dihydrocapsaicin, a capsaicin, is a potent and selective TRPV1 (transient receptor potential vanilloid channel 1) agonist. Dihydrocapsaicin reduces AIF, Bax, and Caspase-3 expressions, and increased Bcl-2, Bcl-xL and p-Akt levels. Dihydrocapsaicin enhances the hypothermia-induced neuroprotection following ischemic stroke via PI3K/Akt regulation in rat .

HY-106950

Fosfructose Diphosphofructose; Esafosfan; FDP	Cardiovascular Disease Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Source Classification	Toll-like Receptor (TLR) COX
Fosfructose is an orally active cyclooxygenase-2 inhibitor and Toll-like receptor 4 modulator. Fosfructose reduces the expression of cyclooxygenase-2, thereby decreasing prostaglandin production. By inhibiting the Toll-like receptor 4 signaling pathway, Fosfructose downregulates LPS-induced adhesion molecule expression. Fosfructose is applicable to research related to ischemic stroke, epilepsy, sepsis, myocardial injury, osteoporosis, and ultraviolet B-induced skin damage .

HY-113110

Cysteinylglycine L-Cysteinylglycine; Cys-Gly; H-Cys-Gly-OH	Natural Products Human Gut Microbiota Metabolites Microorganisms Disease markers Endocrine diseases Metabolic Disease Nervous System Disorder Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite Reactive Oxygen Species (ROS) DNA/RNA Synthesis
Cysteinylglycine (L-Cysteinylglycine; Cys-Gly) is a dipeptide formed by the peptide bond linkage between cysteine (Cysteine) and glycine (Glycine). Cysteinylglycine is an important metabolic intermediate in the human body, mainly derived from the degradation of glutathione (GSH). Cysteinylglycine reduces ferric iron to ferrous iron, drives the redox cycle of iron, generates reactive oxygen species (ROS), stimulates oxidative reactions, induces lipid peroxidation of human plasma LDL lipoproteins, and causes oxidative damage to DNA bases. Cysteinylglycine can be used as a biomarker to evaluate ischemic heart disease, breast cancer and other conditions .

HY-113218

Acetyl-L-carnitine 2 Publications Verification O-Acetyl-L-carnitine; ALCAR	Natural Products Animals Source Classification	Caspase Apoptosis
Acetyl-L-carnitine (O-Acetyl-L-carnitine; ALCAR) is an orally active mitochondrial energy metabolism regulator and neuroprotectant that can penetrate the blood-brain barrier. Acetyl-L-carnitine selectively enters cells and the brain through the organic cation transporter OCTN2. Acetyl-L-carnitine can participate in fatty acid β-oxidation, promote acetylcholine synthesis, regulate mitochondrial function and inhibit oxidative stress as an acetyl donor. Acetyl-L-carnitine exerts its activity by enhancing energy metabolism, protecting neurons and improving synaptic plasticity. Acetyl-L-carnitine is mainly used in the study of neurodegenerative diseases and metabolic disorder-related diseases such as neonatal hypoxic-ischemic brain damage, Alzheimer's disease, and depression .

HY-B1065

Aceglutamide α-N-Acetyl-L-glutamine; N2-Acetylglutamine	Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Keap1-Nrf2 Akt ASK1 Apoptosis
Aceglutamide (α-N-Acetyl-L-glutamine; N2-Acetylglutamine) is a neuroprotectant that can penetrate the blood-brain barrier. Aceglutamide can enhance the antioxidant systems of glutathione (GSH), thioredoxin (Trx) and Nrf2. Aceglutamide also inhibits ASK1 and TRAF1, activates the Akt/Bcl-2 anti-apoptotic pathway, enhances the activity of antioxidant enzymes and reduces oxidative damage. Aceglutamide can improve neurological deficits after cerebral ischemia, reduce infarct volume, and inhibit neuronal apoptosis, especially substantia nigra dopaminergic neurons. Aceglutamide can reduce cerebral ischemia/reperfusion injury, improve motor dysfunction, and is used in ischemic stroke-related research .

HY-111954

(+)-Erinacin A Erinacine A	Microorganisms Terpenoids Diterpenoids	Apoptosis JNK NF-κB Histone Acetyltransferase NO Synthase Bcl-2 Family p38 MAPK Caspase
(+)-Erinacin A (Erinacine A) is a cyanoditerpenoid isolated from Hericium erinaceus with anticancer, anti-inflammatory and neuroprotective activities. (+)-Erinacin A can induce cancer cell death by activating extrinsic and intrinsic apoptosis pathways. (+)-Erinacin A can also inhibit the expression of NO synthase (iNOS) and the production of nitrotyrosine to exert inflammatory and neuroprotective effects, thereby reducing ischemic brain damage .

HY-N0026

2'-Acetylacteoside 1 Publications Verification 2'-AA	Structural Classification Classification of Application Fields Simple Phenylpropanols Other Diseases Scrophulariaceae Phenylpropanoids Plants Disease Research Fields Brandisia hancei Hook. f. Source Classification	Monoamine Oxidase RANKL/RANK TNF Receptor NF-κB IKK
2'-Acetylacteoside (2'-AA) is a natural compound with oral activity and blood-brain barrier permeability. 2'-Acetylacteosideexhibits MAO‑B inhibitory activity (IC₅₀ = 17.71 μM, K_i = 13.81 μM). 2'-Acetylacteoside downregulates the expression of RANK, TRAF6, NF‑κB, NFATc1 and IKKβ, disrupts the RANKL/RANK interaction, blocks downstream signaling pathways, and increases the level of phosphorylated Akt. 2'-Acetylacteoside possesses potent anti-osteoclastogenic, anti-bone resorptive, pro-neurogenic, neuroprotective and antioxidant activities. 2'-Acetylacteoside can be used in the research of osteoporosis, ischemic stroke and Parkinson's disease .

HY-N0663

Talatisamine	Alkaloids Structural Classification Pyrrole Alkaloids Ranunculaceae Aconitum carmichaeli Debx. Plants Source Classification	Mitochondrial Metabolism Cyclophilin Potassium Channel
Talatisamine is an orally active cyclophilin D activator isolated from the roots of Aconitum carmichaeli Debx. Talatisamine exerts biological functions by activating cyclophilin D, inhibiting Ca ²⁺-dependent opening of the mitochondrial permeability transition pore (mPTP) (IC₅₀=78 μM), and blocking delayed rectifier K ⁺ channels (IC₅₀=146 μM). Talatisamine possesses both antioxidant and membrane-stabilizing properties, effectively inhibits lipid peroxidation and protects mitochondrial membrane function. Talatisamine exhibits multiple activities including antiarrhythmic, hypotensive, anti-inflammatory, anticancer and neuroprotective effects. Talatisamine finds applications in the research of ischemic diseases, rheumatoid arthritis, inflammation-related diseases and Alzheimer's disease .

HY-N0546

Ligustroflavone 2 Publications Verification Nuezhenoside	Flavonoids Oleaceae Classification of Application Fields Flavones Ligustrum lucidum Ait. Phenols Polyphenols Metabolic Disease Plants Disease Research Fields Source Classification	CaSR RIP kinase Mixed Lineage Kinase TGF-beta/Smad
Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the RIPK1/RIPK3/MLKL pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis .

HY-N0249

Saikosaponin C 2 Publications Verification	Triterpenes Structural Classification Terpenoids Umbelliferae Plants Carphephorus corymbosus (Nutt.) Torr. & A.Gray Source Classification	MMP
Saikosaponin C is an orally active MMP-2 inducer. Saikosaponin C induces the survival, growth, migration and capillary tube formation of endothelial cells. Saikosaponin C inhibits the early stage of hepatitis C virus infection. Saikosaponin C can be used in research related to ischemic tissue diseases, chronic kidney diseases and hepatitis C virus infection .

HY-N0378R

D-Mannitol (Standard) 10+ Cited Publications Mannitol(Standard); Mannite (Standard)	Structural Classification Natural Products Microorganisms other families Classification of Application Fields Metabolic Disease Plants Endogenous metabolite Disease Research Fields Sweeteners Source Classification Food Research	Reference Standards Endogenous Metabolite Apoptosis PGC-1α Adrenergic Receptor PKA
D-Mannitol (Standard) is the analytical standard of D-Mannitol (HY-N0378). This product is intended for research and analytical applications. D-Mannitol (Mannitol) is an oral, resistant sugar widely used in the food and pharmaceutical industries to promote the absorption and retention of calcium and magnesium through cecal fermentation, while acting as a osmotic diuretic to reduce tissue edema. D-Mannitol can enhance brown fat formation, improve insulin effect, reduce blood sugar levels, And through the start the β₃-adrenergic receptor (β₃-AR), PGC1α and PKA induced by means of white fat cells into brown fat cells . D-Mannitol is commonly used to maintain osmotic pressure between the plant cytoplasm and the culture medium and protect cells when the cell wall is weakened or even removed .

HY-W016409

Ethyl 3,4-dihydroxybenzoate 1 Publications Verification Protocatechuic acid ethyl ester	Arachis hypogaea L. Classification of Application Fields Leguminosae Phenols Polyphenols Metabolic Disease Plants Disease Research Fields Source Classification	HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) NO Synthase Autophagy Apoptosis
Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits the hydroxylation modification of hypoxia-inducible factor (HIF) by PHD. Ethyl 3,4-dihydroxybenzoate stabilizes HIF-1α by inhibiting PHD, activates downstream pathways to induce autophagy and apoptosis of tumor cells, and regulates inflammatory responses, inhibits the NF-κB pathway, improves vascular permeability, and promotes osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate has anti-tumor, anti-hypoxic injury, and bone metabolism regulation effects. It can also be used in the research of cardiovascular protection (such as reducing myocardial ischemic damage), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema .

HY-N5048

Galloylpaeoniflorin 6'-O-Galloyl paeoniflorin	Structural Classification Paeonia lactiflora Pall. Classification of Application Fields Other Diseases Phenols Polyphenols Plants Paeoniaceae Disease Research Fields Source Classification	NF-κB ERK JNK Nuclear Factor of activated T Cells (NFAT) Keap1-Nrf2 PI3K Akt Reactive Oxygen Species (ROS) Apoptosis DNA/RNA Synthesis
Galloylpaeoniflorin (6'-O-Galloyl paeoniflorin) is an orally active galloylated derivative of Paeoniflorin (HY-N0293) found in peony roots with various anti-inflammatory and antioxidant activities. Galloylpaeoniflorin suppresses RANKL-induced activation of ERK, JNK, c-Fos, c-Jun, and NFATc1, and reduces osteoclast-specific gene expression. Galloylpaeoniflorin activates Nrf2 and PI3K/Akt pathways, inhibits NF-κB activation, and scavenges ROS to reduce oxidative DNA, lipid, and protein damage. Galloylpaeoniflorin attenuates neuroinflammation, inhibits apoptosis, reduces Helicobacter pylori-induced gastric mucosa injury and UVB-induced cell damage. Galloylpaeoniflorin can be used for the research of osteoporosis, gastritis, ischemic stroke and skin diseases .

HY-N2484

Methylnissolin 2 Publications Verification Astrapterocarpan	Cardiovascular Disease Structural Classification Monophenols Flavonoids Classification of Application Fields Leguminosae Phenols Astragalus membranaceus var. mongholicus (Bunge)P.K.Hsiao Plants Other Flavonoids Disease Research Fields Source Classification	PDGFR ERK
Methylnissolin (Astrapterocarpan) is an osteoclast inhibitor with anti-inflammatory, neuroprotective and antioxidant activities. Methylnissolin downregulates the activation of the MAPK and PI3K/AKT pathways, inhibits the phosphorylation of MAPK1 and AKT1, and blocks PDGF-BB-induced phosphorylation of ERK1/2. Methylnissolin reduces the expression and secretion of proinflammatory mediators, decreases intracellular ROS levels, upregulates antioxidant enzymes, and downregulates osteoclastogenesis markers. Methylnissolin is applicable to research related to ischemic stroke, osteoporosis, cardiovascular diseases, skin aging, etc.

HY-P2159

Dynorphin A (1-8)	Structural Classification Natural Products Neurological Disease Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification	Opioid Receptor Endogenous Metabolite
Dynorphin A (1-8) is a ligand with preference for the κ-opioid receptor, and its IC₅₀ value against human placental κ-opioid receptor is 330 nM. Dynorphin A (1-8) mediates neuroprotective effects by inhibiting oxidative stress, suppressing apoptosis, and competitively displacing the binding of κ partial agonists. Dynorphin A (1-8) is the dominant opioid peptide in human placental villi and tissue extracts; it undergoes rapid hydrolysis and can enter the central nervous system via intranasal administration. Dynorphin A (1-8) can be used in studies related to ischemic stroke .

HY-N0390R

L-Glutamine (Standard) Maximum Cited Publications 27 Publications Verification L-Glutamic acid 5-amide (Standard)	Structural Classification Human Gut Microbiota Metabolites Immune System Disorder Microorganisms Disease markers Endocrine diseases Amino acids Nervous System Disorder Endogenous metabolite Cardiovascular System Disorder Cancer Source Classification	Reference Standards mGluR Ferroptosis Environmental Pollutants Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase mTOR STAT NF-κB
L-Glutamine (Standard) is the analytical standard of L-Glutamine (HY-N0390). This product is intended for research and analytical applications. L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-N1910

4'-O-Methylbavachalcone 4 Publications Verification	Infection Structural Classification Chalcones Flavonoids Classification of Application Fields Leguminosae Phenols Polyphenols Psoralea corylifolia L. Plants Disease Research Fields Source Classification	SARS-CoV Virus Protease Succinate Receptor 1 ERK
4'-O-Methylbavachalcone is an orally active prenylated flavonoid that inhibits the activity of SARS-CoV papain-like protease (PLpro), with an IC₅₀ of 10.1 μM and a K_i of 4.6 μM. 4'-O-Methylbavachalcone inhibits poly (ADP-ribose) polymerase-mediated cell death (parthanatos), reduces cerebral infarct volume, binds to the orthosteric site of SUCNR1, blocks the interaction between succinate and SUCNR1, inhibits SUCNR1 activity, blocks the nuclear translocation of NFATc4, suppresses the activation of the ERK1/2 signaling pathway, inhibits cardiomyocyte hypertrophy and restores the expression of α-actinin. 4'-O-Methylbavachalcone can be used in studies related to ischemic stroke, SARS-CoV and cardiomyocyte hypertrophy .

HY-N2125

Parishin C	Structural Classification Gastrodia elata Bl. Orchidaceae Phenols Plants Source Classification	5-HT Receptor iGluR Caspase Interleukin Related TNF Receptor SOD NF-κB
Parishin C is a brain-penetrant major bioactive component found in Gastrodia elata Blume. Parishin C is a 5-HT1A receptor agonist with an EC₅₀ of 34 nM. Parishin C has antipsychotic and neuroprotective effects. Parishin C protects against Aβ-induced long-term potentiation damage and NMDA receptor current impairment. Parishin C reduces oxidative stress, pro-inflammatory cytokine levels, caspase activity, brain water content, and cerebral infarct volume; increases antioxidant enzyme activity and BDNF levels; improves nerve function and histopathological brain damage. Parishin C attenuates phencyclidine-induced immobility time increases, sociability deficits, and visual recognition memory impairment. Parishin C can be used for the research of ischemic stroke, Alzheimer's disease, and schizophrenia-like psychosis .

HY-N3307

(+)-Medioresinol 1 Publications Verification	Cardiovascular Disease Oleaceae Fraxinus mandshurica Rupr. Neurological Disease Classification of Application Fields Phenols Polyphenols Plants Disease Research Fields Source Classification	Bacterial Fungal Reactive Oxygen Species (ROS) Apoptosis MMP Interleukin Related PI3K Akt mTOR PPAR PGC-1α Pyroptosis
(+)-Medioresinol is a furofuran-type lignan with antifungal and antibacterial properties. (+)-Medioresinol synergizes with antibiotics to exert antimicrobial and antibiofilm effects. (+)-Medioresinol induces intracellular ROS accumulation and mitochondrial-mediated apoptosis in Candida albicans. (+)-Medioresinol inhibits LPS (HY-D1056)-stimulated IL-12p40 production. (+)-Medioresinol is a PGC-1α activator that protects against endothelial cell pyroptosis in ischemic stroke via the PPARα-GOT1 axis. (+)-Medioresinol can be used in research on fungal and bacterial infection, inflammation, and ischemic stroke .

HY-N2000

Bellidifolin 1 Publications Verification	Infection Structural Classification Xanthones Classification of Application Fields Swertia bimaculata (Sieb. et Zucc.) Hook. f. et Thoms. ex C. B. Clark Gentianaceae Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields Source Classification	STAT PI3K mTOR Akt
Bellidifolin is an orally active compound with antiproliferative, anti-inflammatory and antioxidant properties. Bellidifolin modulates key signaling pathways including STAT3, PI3K-Akt, mTOR and BRD4, and inhibits the viral protein R (Vpr). Bellidifolin induces cell cycle arrest and apoptosis, exerts significant antifibrotic effects, and protects the heart, liver and nervous system. Bellidifolin is applicable to the research of various diseases such as lung cancer, non-alcoholic fatty liver disease, myocardial hypertrophy and ischemic cranial nerve injury .

HY-N4205

Tetrahydropiperine	Alkaloids Piperidine Alkaloids Classification of Application Fields Piperaceae Plants Disease Research Fields Piper nigrum Linn. Source Classification Cancer	Cytochrome P450
Tetrahydropiperine is an orally effective, selective inhibitor of NF-κB and MAPKs<、b>, and an activator of the PI3K/Akt/mTOR<、b> pathway. Tetrahydropiperine reduces the production of pro-inflammatory cytokines such as TNF-α, IL-6, and nitric oxide (NO) by inhibiting the nuclear translocation of NF-κB and the phosphorylation of MAPKs such as ERK, JNK, and p38. At the same time, Tetrahydropiperine inhibits excessive autophagy by activating the PI3K/Akt/mTOR pathway, protecting neurons from oxidative damage. Tetrahydropiperine has anti-inflammatory, anti-apoptotic, and neuroprotective effects, and is mainly used in the study of inflammatory diseases (such as endotoxemia, arthritis) and neurological diseases such as ischemic stroke .

HY-16637D

Folic acid disodium 20+ Cited Publications Vitamin B9 disodium; Vitamin M disodium	Natural Products Neurological Disease Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification Cancer	Endogenous Metabolite DNA/RNA Synthesis
Folic acid disodium (Vitamin B9 disodium; Vitamin M disodium) is an orally active disodium salt form of Folic acid (HY-16637) with an intrinsic dissolution rate (IDR) of 4.96·10 ⁵ g/s . Folic acid disodium serves as cofactor in single-carbon transfer reactions and exhibits protective effects against neural tube defects, ischemic events, and cancer. Folate acid disodium overload leads to impaired brain development in embryogenesis and promotes growth of precancerous altered cells. Folic acid deficiency leads to megaloblastic anemia .

HY-N4098

Incensole Acetate	other families Terpenoids Diterpenoids Plants Source Classification	Apoptosis
Incensole acetate is a main constituent of Boswellia carterii resin, has neuroprotective effects against neuronal damage in traumatic and ischemic head injury. Incensole acetate reduces Aβ25–35-triggered apoptosis in hOBNSCs .

HY-106784A

(E)-Ajoene	Natural Products Allium sativum L. Plants Amaryllidaceae Source Classification	Fungal Apoptosis
(E)-Ajoene is a oxygenated ajoene and organosulfur compound, which can be acquired via allicin decomposing. The polysulfides from garlic can be converted by human red blood cells into hydrogen sulfide (H2S) and allyl glutathione. (E)-Ajoene has been proved to show neuroprotective effects against ischemic damage. (E)-Ajoene is orally active to inhibit lipid peroxidation. (E)-Ajoene increases the number of cresyl violet-positive neurons and decreases the number of reactive gliosis in the CA1 region .

HY-N12378

β-Patchoulene	Other Terpenoids Structural Classification Entada phaseoloides (L.) Merr. Terpenoids Labiatae Plants Source Classification	NF-κB Toll-like Receptor (TLR) PKA Epigenetic Reader Domain Keap1-Nrf2 Sirtuin AMPK Caspase FASTK ERK ROCK Apoptosis
β-Patchoulene is an orally active anti-inflammatory, antioxidant, and anti-apoptotic agent. β-Patchoulene inhibits the NF-κB, TLR4, and cAMP/PKA/CREB signaling pathways; activates the Sirt1/Nrf2 and AMPK signaling pathways; and targets Fas/FasL, Caspase-3, ERK1/2, ROCK1/MLC2 for inhibition. β-Patchoulene regulates cytokine secretion, inflammatory cell infiltration, lipid peroxidation, cell polarization, gut microbiota, and lipid metabolism, restores barrier function, mitochondrial function, and cell viability, and exhibits repellent activity against Spodoptera exigua larvae. β-Patchoulene can be used in research related to various inflammatory, ischemic, fibrosis-associated diseases, as well as hepatocellular carcinoma .

HY-30004R

1-Aminocyclopropane-1-carboxylic acid (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
1-Aminocyclopropane-1-carboxylic acid (Standard) is the analytical standard of 1-Aminocyclopropane-1-carboxylic acid. This product is intended for research and analytical applications. 1-Aminocyclopropane-1-carboxylic acid is an endogenous metabolite. In the presence of low concentrations (1 μM) of glutamate, 1-Aminocyclopropane-1-carboxylic acid acts as a small molecule agonist of NMDA receptors with an EC50 of 0.7-0.9 μM. At high concentrations (10 μM) of glutamate, 1-Aminocyclopropane-1-carboxylic acid acts as a competitive antagonist of NMDA receptors with an EC50 of 81.6 nM. 1-Aminocyclopropane-1-carboxylic acid exerts neuroprotective activity by moderately activating NMDA receptors to prevent neuronal cell death in ischemic animal models. Additionally, 1-Aminocyclopropane-1-carboxylic acid is an antagonist of NMDA receptors, inducing blood pressure reduction and antioxidant effects in stroke-prone hypertensive rats. 1-Aminocyclopropane-1-carboxylic acid enhances object recognition memory and cognitive flexibility dependent on the prefrontal cortex, but does not affect impulsivity nor exhibit an antipsychotic-like profile. 1-Aminocyclopropane-1-carboxylic acid shows promise for research in the field of neurotoxicity. .

HY-142019

Tanshinol borneol ester	Labiatae Samanea saman (Jacq.) Merr. Phenols Polyphenols Plants Source Classification	Akt AMPK
Tanshinol borneol ester, an angiogenesis stimulator, promoted multiple key steps of angiogenesis through Akt and MAPK signalling pathways. Tanshinol borneol ester has anti-ischemic and anti-atherosclerosis activities .

HY-N9347

Stepharine 3 Publications Verification	Cardiovascular Disease Alkaloids other families Classification of Application Fields Plants Isoquinoline Alkaloids Disease Research Fields Source Classification	Toll-like Receptor (TLR)
Stepharine, an natural alkaloid, directly interactes with TLR4 and binds to the TLR4/MD2 complex (TLR4 inhibitor). Stepharine possesses anti-aging, anti-viral and anti-hypertensive effects .

HY-113329R

Guanidinoethyl sulfonate (Standard) Taurocyamine (Standard)	Structural Classification Natural Products Other disease Disease markers Endogenous metabolite	Endogenous Metabolite Reference Standards
Guanidinoethyl sulfonate (Standard) is the analytical standard of Guanidinoethyl sulfonate. This product is intended for research and analytical applications. Guanidinoethyl sulfonate is an orally available, blood-brain permeable competitive inhibitor of taurine transporters and a competitive antagonist of glycine receptors (GlyR) (IC50=565 μM). Guanidinoethyl sulfonate has both weak agonist and antagonist effects on GABAA receptors. Guanidinoethyl sulfonate inhibits taurine transmembrane transport and competitively binds to the GlyR ligand binding domain, thereby blocking glycine-mediated chloride influx, and may regulate brain pH to exert neuroprotective effects. Guanidinoethyl sulfonate can be used for neuroprotection studies of ischemic brain injury .

HY-N8598

Caulophine	Alkaloids Caulophyllum robustum Maxim. Plants Berberidaceae Source Classification	Others
Caulophine is a fluoroketone alkaloid isolated from Caulophyllum robustum MAXIM. Caulophine has antioxidant activity and the ability to protect cardiomyocytes from oxidative and ischemic damage, providing potential value for coronary heart disease research .

HY-N16650

Bisadinrone A	Structural Classification Terpenoids Sesquiterpenes Plants Curcuma longa Source Classification Zingiberaceae	Lactate Dehydrogenase
Bisadinrone A is a sesquiterpene found in Curcuma longa. Bisadinrone A can inhibit LDH release and shows significant anti-myocardial ischemia-reperfusion injury activity. Bisadinrone A can be used for the research of cardiovascular disease, such as ischemic heart disease .

HY-113110A

Cysteinylglycine TFA L-Cysteinylglycine TFA; Cys-Gly TFA; H-Cys-Gly-OH TFA	Structural Classification Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite Reactive Oxygen Species (ROS) DNA/RNA Synthesis
Cysteinylglycine (L-Cysteinylglycine; Cys-Gly) TFA is a dipeptide formed by the peptide bond connection of cysteine and glycine. Cysteinylglycine TFA is an important metabolic intermediate in the human body, mainly derived from the degradation of glutathione (GSH). Cysteinylglycine TFA can reduce trivalent iron to divalent iron, driving the redox cycle of iron, generating reactive oxygen species (ROS), stimulating oxidative reactions, inducing lipid peroxidation in human plasma LDL lipoproteins, and causing oxidative damage to DNA base. Cysteinylglycine TFA can be used as a biomarker to assess ischemic heart disease and breast cancer, etc ^[1][2][3][4].

HY-N2720

6-O-Caffeoylarbutin Robustaside B	Structural Classification Classification of Application Fields Simple Phenylpropanols Phenols Polyphenols Metabolic Disease Phenylpropanoids Ericaceae Plants Disease Research Fields Source Classification Vaccinium dunalianum Wight	PI3K Reactive Oxygen Species (ROS)
6-O-Caffeoylarbutin (Robustaside B) possesses antioxidant activity . 6-O-Caffeoylarbutin ameliorates neurological functions and deficits in ischemic mice.

HY-N0546R

Ligustroflavone (Standard) Nuezhenoside (Standard)	Structural Classification Flavonoids Oleaceae Flavones Ligustrum lucidum Ait. Phenols Polyphenols Plants Source Classification	Reference Standards CaSR RIP kinase Mixed Lineage Kinase TGF-beta/Smad
Ligustroflavone (Standard) is the analytical standard of Ligustroflavone (HY-N0546). This product is intended for research and analytical applications. Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the RIPK1/RIPK3/MLKL pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis .

HY-N0361R

Dihydrocapsaicin (Standard)	Alkaloids Structural Classification Monophenols Capsicum annuum L. Other Alkaloids Phenols Solanaceae Plants Source Classification	Reference Standards TRP Channel Reactive Oxygen Species (ROS) Apoptosis Caspase Bcl-2 Family Akt PI3K
Dihydrocapsaicin (Standard) is the analytical standard of Dihydrocapsaicin. This product is intended for research and analytical applications. Dihydrocapsaicin, a capsaicin, is a potent and selective TRPV1 (transient receptor potential vanilloid channel 1) agonist. Dihydrocapsaicin reduces AIF, Bax, and Caspase-3 expressions, and increased Bcl-2, Bcl-xL and p-Akt levels. Dihydrocapsaicin enhances the hypothermia-induced neuroprotection following ischemic stroke via PI3K/Akt regulation in rat .

HY-N8931

Monomethyl lithospermate Lithospermic acid monomethyl ester	Labiatae Samanea saman (Jacq.) Merr. Phenols Polyphenols Plants Source Classification	Akt
Monomethyl lithospermate activates the PI3K/AKT pathway, which plays a protective role in nerve injury. Monomethyl lithospermate can improve the survival ability of SHSY-5Y cells, inhibit the breakdown of mitochondrial membrane potential (MMOP) and inhibit cell apoptosis. Monomethyl lithospermate also reduced the level of oxidative stress in the brain tissue of rats with middle artery occlusion (MCAO) and improved nerve damage in rats with ischemic stroke (IS) .

HY-113110R

Cysteinylglycine (Standard) L-Cysteinylglycine (Standard); Cys-Gly (Standard); H-Cys-Gly-OH (Standard)	Natural Products Human Gut Microbiota Metabolites Microorganisms Disease markers Endocrine diseases Nervous System Disorder Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Reactive Oxygen Species (ROS) DNA/RNA Synthesis
Cysteinylglycine (Standard) is the analytical standard of Cysteinylglycine. This product is intended for research and analytical applications. Cysteinylglycine is a dipeptide formed by the peptide bond linkage between cysteine (Cysteine) and glycine (Glycine). Cysteinylglycine is an important metabolic intermediate in the human body, mainly derived from the degradation of glutathione (GSH). Cysteinylglycine reduces ferric iron to ferrous iron, drives the redox cycle of iron, generates reactive oxygen species (ROS), stimulates oxidative reactions, induces lipid peroxidation of human plasma LDL lipoproteins, and causes oxidative damage to DNA bases. Cysteinylglycine can be used as a biomarker to evaluate ischemic heart disease, breast cancer and other conditions .

HY-B1614R

Clenbuterol hydrochloride (Standard) NAB-365 hydrochloride (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Adrenergic Receptor
Clenbuterol (hydrochloride) (Standard) is the analytical standard of Clenbuterol (hydrochloride). This product is intended for research and analytical applications. Clenbuterol (NAB-365) hydrochloride, a selective β2-adrenergic agonist, enhances skeletal muscle strength and hypertrophy. Clenbuterol hydrochloride induces growth factor mRNA, activates astrocytes, and protects rat brain tissue against ischemic damage .

HY-N13251

Verbena Extract	Cardiovascular Disease Classification of Application Fields Verbenaceae Plants Disease Research Fields Source Classification	Others
Verbena Extract is a verbena extract. Verbena Extract is a potential anti-ischemic stroke agent, and its mechanism may be related to IL17A-mediated neuroinflammation regulation. .

HY-N4098R

Incensole Acetate (Standard)	other families Terpenoids Diterpenoids Plants Source Classification	Reference Standards Apoptosis
Incensole Acetate (Standard) is the analytical standard of Incensole Acetate. This product is intended for research and analytical applications. Incensole acetate is a main constituent of Boswellia carterii resin, has neuroprotective effects against neuronal damage in traumatic and ischemic head injury. Incensole acetate reduces Aβ25–35-triggered apoptosis in hOBNSCs .

HY-N15005

Espicufolin	Monophenols Microorganisms Phenols Source Classification	Others
Espicufolin is a neuroprotective substance that can be found in Streptomyces sp:cu39. Espicufolin can inhibit glutamate toxicity, thereby reducing or overcoming cerebral ischemic damage, with a toxicity EC₅₀ value of 40 nM for N18-RE-105 cells. Espicufolin can be used in the study of neurodegenerative diseases .

Cat. No.	Product Name	Chemical Structure

HY-N0390S1

L-Glutamine-13C5

Maximum Cited Publications

9 Publications Verification

L-Glutamine- ¹³C₅ is the ¹³C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-N0390S

L-Glutamine-15N

3 Publications Verification

L-Glutamine- ¹⁵N is the ¹⁵N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-N0390S8

L-Glutamine-15N2

1 Publications Verification

L-Glutamine- ¹⁵N₂ is the ¹⁵N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-N0390S9

L-Glutamine-15N-1

3 Publications Verification

L-Glutamine- ¹⁵N-1 is the ¹⁵N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-N0390S2

L-Glutamine-d5

1 Publications Verification

L-Glutamine-d₅ is the deuterium labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-N0390S6

L-Glutamine-13C5,15N2

L-Glutamine- ¹³C₅, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-B0762S

Acetyl-L-carnitine-d3 hydrochloride

Acetyl-L-carnitine-d₃ (O-Acetyl-L-carnitine-d₃) hydrochloride is the deuterium labeled Acetyl-L-carnitine hydrochloride (HY-B0762). Acetyl-L-carnitine (O-Acetyl-L-carnitine; ALCAR) hydrochloride is an orally active mitochondrial energy metabolism regulator and neuroprotectant that can penetrate the blood-brain barrier. Acetyl-L-carnitine hydrochloride selectively enters cells and the brain through the organic cation transporter OCTN2. Acetyl-L-carnitine hydrochloride can participate in fatty acid β-oxidation, promote acetylcholine synthesis, regulate mitochondrial function and inhibit oxidative stress as an acetyl donor. Acetyl-L-carnitine hydrochloride exerts its activity by enhancing energy metabolism, protecting neurons and improving synaptic plasticity. Acetyl-L-carnitine hydrochloride is mainly used in the study of neurodegenerative diseases and metabolic disorder-related diseases such as neonatal hypoxic-ischemic brain damage, Alzheimer's disease, and depression .

HY-N0390S5

L-Glutamine-1-13C

1 Publications Verification

L-Glutamine-1- ¹³C is the ¹³C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-N0390S4

L-Glutamine-5-13C

L-Glutamine-5- ¹³C is the ¹³C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-B0762S1

Acetyl-L-carnitine-d3-1 hydrochloride

Acetyl-L-carnitine-d₃-1 (O-Acetyl-L-carnitine-d₃-1) hydrochloride is the deuterium labeled Acetyl-L-carnitine hydrochloride (HY-B0762). Acetyl-L-carnitine (O-Acetyl-L-carnitine; ALCAR) hydrochloride is an orally active mitochondrial energy metabolism regulator and neuroprotectant that can penetrate the blood-brain barrier. Acetyl-L-carnitine hydrochloride selectively enters cells and the brain through the organic cation transporter OCTN2. Acetyl-L-carnitine hydrochloride can participate in fatty acid β-oxidation, promote acetylcholine synthesis, regulate mitochondrial function and inhibit oxidative stress as an acetyl donor. Acetyl-L-carnitine hydrochloride exerts its activity by enhancing energy metabolism, protecting neurons and improving synaptic plasticity. Acetyl-L-carnitine hydrochloride is mainly used in the study of neurodegenerative diseases and metabolic disorder-related diseases such as neonatal hypoxic-ischemic brain damage, Alzheimer's disease, and depression .

HY-N0390S3

L-Glutamine-13C5,15N2,d5

L-Glutamine- ¹³C₅, ¹⁵N₂,d₅ is the deuterium, ¹³C-, and ¹⁵N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-151546S

MRS4596-d4
MRS4596-d₄ is the deuterium labeled MRS4596 (HY-151546). MRS4596 is a potent and selective P2X4 receptor antagonist with an IC₅₀ value of 1.38 μM for human P2X4 receptor. MRS4596 has neuroprotective and neuro-rehabilitative activities in ischemic stroke model. MRS4596 can be used in research of ischemic stroke .

HY-146925S

15:0 Lyso PC-d5

15:0 Lyso PC-d₅ is deuterium labeled 15:0 Lyso PC (HY-W329357). 15:0 Lyso PC is a lysophosphatidylcholine (Lyso PC), a product of phospholipase A2 (PLA2) hydrolysis of phosphatidylcholine (PC) and is involved in cell membrane remodeling and inflammatory signaling. 15:0 Lyso PC demonstrates significant lipid metabolism disturbances in the serum of patients with ischemic heart disease (IHD) and ischemic cardiomyopathy (ICM). 15:0 Lyso PC can be used as a lipid biomarker for cardiovascular disease.

HY-151547S

MRS4719-d3

MRS4719-d₃ is the deuterium labeled MRS4719 (HY-151547). MRS4719 is a potent P2X4 receptor antagonist with an IC₅₀ value of 0.503 μM for human P2X4 receptor. MRS4719 can reduce infarct volume and reduce brain atrophy, showing neuroprotective and neuro-rehabilitative activities in ischemic stroke model. MRS4719 also reduces ATP-induced [Ca ²⁺]_i influx in primary human monocyte-derived macrophages. MRS4719 can be used to research ischemic stroke .

HY-B0531S

Triflusal-d3

Triflusal-d₃ is deuterium labeled Triflusal (HY-B0531). Triflusal is an orally bioavailable, blood-brain barrier-permeable dual Cyclooxygenase-1 (COX-1)/cAMP phosphodiesterase inhibitor. Triflusal inhibits platelet aggregation, NF-κB activation, iNOS activity, and prostaglandin synthesis in ischaemic tissue. Triflusal stimulates neutrophil nitric oxide production, eNOS protein expression, and cNOS activity. Triflusal alleviates cerebral ischemic injury in rats and ameliorates pathological lesions and related gene expression in transgenic Alzheimer’s disease models. Triflusal can be used for the research of thromboembolic/ischemic cardiovascular and cerebrovascular diseases, and Alzheimer’s disease .

HY-W017540S

Cyclocreatine-13C3

Cyclocreatine- ¹³C₃ is the ¹³C-labeled Cyclocreatine (HY-W017540). Cyclocreatine, a creatine analogue, acts as a brain-penetrant and potent bioenergetic protective agent by providing high levels of ATP. Cyclocreatine can be phosphorylated and dephosphorylated by creatine kinases. Cyclocreatine suppresses creatine metabolism ameliorating the cognitive, autistic and epileptic phenotype in a mouse model of creatine transporter defciency. Cyclocreatine protects against ischemic injury and enhances cardiac recovery during early reperfusion in dogs and rats. Cyclocreatine decreases plaque-adjacent neuronal dystrophy in TREM2-deficient mice with amyloid-β pathology. Cyclocreatine is proming for research of ischemic heart disease, cardiovascular diseases, Alzheimer’s disease and other neurodegenerative diseases associated with microglial dysfunction, prostate cancer .

HY-N0361S

Dihydrocapsaicin-d3

Dihydrocapsaicin-d₃ is the deuterium labeled Dihydrocapsaicin (HY-N0361) . Dihydrocapsaicin, a capsaicin, is a potent and selective TRPV1 (transient receptor potential vanilloid channel 1) agonist. Dihydrocapsaicin reduces AIF, Bax, and Caspase-3 expressions, and increased Bcl-2, Bcl-xL and p-Akt levels. Dihydrocapsaicin enhances the hypothermia-induced neuroprotection following ischemic stroke via PI3K/Akt regulation in rat .

HY-117281S1

Moexipril-d3
Moexipril-d₃ is deuterated labeled Moexipril (HY-117281). Moexipril is an orally active inhibitor of angiotensin-converting enzyme (ACE), and becomes effective by being hydrolyzed to moexiprila hydrochloride. Moexipril exhibits antihypertensive and neuroprotective effects ^- .

HY-W765177

Acetyl-L-carnitine hydrochloride-13C3

Acetyl-L-carnitine hydrochloride- ¹³C₃ (O-Acetyl-L-carnitine hydrochloride- ¹³C₃) is the ¹³C-labeled Acetyl-L-carnitine hydrochloride (HY-B0762). Acetyl-L-carnitine (O-Acetyl-L-carnitine; ALCAR) hydrochloride is an orally active mitochondrial energy metabolism regulator and neuroprotectant that can penetrate the blood-brain barrier. Acetyl-L-carnitine hydrochloride selectively enters cells and the brain through the organic cation transporter OCTN2. Acetyl-L-carnitine hydrochloride can participate in fatty acid β-oxidation, promote acetylcholine synthesis, regulate mitochondrial function and inhibit oxidative stress as an acetyl donor. Acetyl-L-carnitine hydrochloride exerts its activity by enhancing energy metabolism, protecting neurons and improving synaptic plasticity. Acetyl-L-carnitine hydrochloride is mainly used in the study of neurodegenerative diseases and metabolic disorder-related diseases such as neonatal hypoxic-ischemic brain damage, Alzheimer's disease, and depression .

HY-N0390S7

L-Glutamine-15N2,d5

L-Glutamine- ¹⁵N₂,d₅ is the deuterium and ¹⁵N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-W778057

Ethyl 3,4-Dihydroxybenzoate-13C3

Ethyl 3,4-Dihydroxybenzoate- ¹³C₃ (Protocatechuic acid ethyl ester- ¹³C₃) is the ¹³C-labeled Ethyl 3,4-dihydroxybenzoate (HY-W016409). Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits the hydroxylation modification of hypoxia-inducible factor (HIF) by PHD. Ethyl 3,4-dihydroxybenzoate stabilizes HIF-1α by inhibiting PHD, activates downstream pathways to induce autophagy and apoptosis of tumor cells, and regulates inflammatory responses, inhibits the NF-κB pathway, improves vascular permeability, and promotes osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate has anti-tumor, anti-hypoxic injury, and bone metabolism regulation effects. It can also be used in the research of cardiovascular protection (such as reducing myocardial ischemic damage), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema .

HY-B1218S

Sulfaphenazole-d4

Sulfaphenazole-d₄ is the deuterium labeled Sulfaphenazole (HY-B1218). Sulfaphenazole is a selective inhibitor of human cytochrome P450 (CYP) 2C9 enzyme. Sulfaphenazole is a cytoprotective agent against light-induced death of photoreceptors. Sulfaphenazole inhibits light-induced necrosis and mitochondrial stress-initiated apoptosis. Sulfaphenazole is an off patent sulfonamide antibiotic and demonstrates bactericidal activity through enhanced M1 macrophage activity. Sulfaphenazole can significantly reduce infarct size and restore post-ischemic coronary flow following ischemia and reperfusion .

HY-W709349S

Flupirtine-d6 hydrochloride

Flupirtine-d₆ (D 9998-d₆) hydrochloride is the deuterium labeled Flupirtine hydrochloride (HY-W709349). Flupirtine hydrochloride is an orally active, blood-brain barrier-crossing non-opioid analgesic and neuroprotective agent. Flupirtine hydrochloride is a neuronal potassium channel opener (Kv7 activator), a NMDA receptor antagonist and a GABA receptor activator. Flupirtine hydrochloride stabilizes blood-brain-barrier integrity, reduces oxidative stress and brain leukocyte infiltration, enhances angioneurogenesis, suppresses calcium influx, stabilizes neuronal resting membrane potential, and counteracts focal cerebral ischemia. Flupirtine hydrochloride exhibits analgesic, muscle relaxant properties, protects neurons from excitotoxic, ischemic, or cytokine-mediated death. Flupirtine hydrochloride functions as a non-opioid analgesic without antipyretic or antiphlogistic properties, shows no relevant affinity to opiate receptor. Flupirtine hydrochloride can be used for the research of focal cerebral ischemia, pain, Alzheimer’s disease, or multiple sclerosis .

Cat. No.	Product Name		Classification

HY-B0762

Acetyl-L-carnitine hydrochloride 2 Publications Verification O-Acetyl-L-carnitine hydrochloride; ALCAR hydrochloride		Cationic Lipids
Acetyl-L-carnitine (O-Acetyl-L-carnitine; ALCAR) hydrochloride is an orally active mitochondrial energy metabolism regulator and neuroprotectant that can penetrate the blood-brain barrier. Acetyl-L-carnitine hydrochloride selectively enters cells and the brain through the organic cation transporter OCTN2. Acetyl-L-carnitine hydrochloride can participate in fatty acid β-oxidation, promote acetylcholine synthesis, regulate mitochondrial function and inhibit oxidative stress as an acetyl donor. Acetyl-L-carnitine hydrochloride exerts its activity by enhancing energy metabolism, protecting neurons and improving synaptic plasticity. Acetyl-L-carnitine hydrochloride is mainly used in the study of neurodegenerative diseases and metabolic disorder-related diseases such as neonatal hypoxic-ischemic brain damage, Alzheimer's disease, and depression .

HY-137500

NT1-014B 1 Publications Verification		Cationic Lipids
NT1-014B is a tryptamine-derived lipidoid. NT1-014B incorporates NT-lipidoid into BBB-impermeable lipid nanoparticles (LNPs), enabling the LNPs to cross the BBB. NT1-014B enhances brain delivery via intravenous injection. NT1-014B can be used in ischemic stroke research .

HY-108746

Defibrotide sodium		Antisense Oligonucleotides
Defibrotide sodium is a complex mixture of single stranded polydeoxyribonucleotides. Defibrotide sodium has liver protection, anti-inflammatory, antithrombotic, profibrinolytic, and anti-ischemic properties. Defibrotide sodium can be used for sinusoidal obstruction syndrome (SOS)/veno-occlusive disease (VOD) research .

HY-172705

DSPE-PEG2000-RVG29		Pegylated Lipids
DSPE-PEG2000-RVG29 is a PEG conjugate composed of DSPE and rabies virus glycoprotein 29 (RVG29). RVG29 specifically binds to nicotinic acetylcholine receptors (nAChR) at the blood-brain barrier (BBB), crosses the BBB, and mediates receptor-dependent transcytosis. DSPE-PEG2000-RVG29 can be used for brain-targeted drug delivery, surface modification of nanocarriers, as well as gene and nucleic acid delivery. DSPE-PEG2000-RVG29 is applicable to research related to hypoxic-ischemic brain injury, Parkinson's disease, and other conditions .

HY-172687

DSPE-PEG2000-CSTSMLKAC		Pegylated Lipids
DSPE-PEG2000-CSTSMLKAC is a PEG compound which composed of DSPE and a peptide (CSTSMLKAC). DSPE-PEG2000-CSTSMLKAC can be used for drug delivery DSPE-PEG2000-CSTSMLKAC enables targeted delivery of associated nanoliposomes to ischemic myocardial cells .

HY-158820

Cosdosiran 1 Publications Verification QPI-1007		siRNAs siRNA drugs
Cosdosiran is a chemically modified siRNA designed to temporarily inhibit expression of the caspase 2 protein and can be used for the study of nonarteritic anterior ischemic optic neuropathy and other optic neuropathies such as glaucoma that result in the death of retinal ganglion cells.

HY-158820A

Cosdosiran sodium 1 Publications Verification QPI-1007 sodium		siRNAs siRNA drugs
Cosdosiran sodium is a chemically modified siRNA designed to temporarily inhibit expression of the caspase 2 protein and can be used for the study of nonarteritic anterior ischemic optic neuropathy and other optic neuropathies such as glaucoma that result in the death of retinal ganglion cells.

HY-172687A

DSPE-PEG3400-CSTSMLKAC		Pegylated Lipids
DSPE-PEG3400-CSTSMLKAC is a PEG compound which composed of DSPE and a peptide (CSTSMLKAC). CSTSMLKAC is capable of mediating selective homing of phage to ischemic heart tissue. DSPE-PEG3400-CSTSMLKAC can be used for drug delivery .

HY-172688

DSPE-PEG5000-CSTSMLKAC		Pegylated Lipids
DSPE-PEG5000-CSTSMLKAC is a PEG compound which composed of DSPE and a peptide (CSTSMLKAC). CSTSMLKAC is capable of mediating selective homing of phage to ischemic heart tissue. DSPE-PEG5000-CSTSMLKAC can be used for drug delivery .

HY-161703

2-Hydroxy-3′-O-methyladenosine		Nucleoside Analogs Adenosine
2-Hydroxy-3′-O-methyladenosine is a synthetic intermediate product that can be used in the research of ischemic heart disease, cerebrovascular disease, kidney disease, inflammatory allergies and other diseases. 2-phenylamino-N6,2'-O-dimethyladenosine produced from 2-Hydroxy-3′-O-methyladenosine is an inhibitor of adenosine deaminase with a Ki of 13 nM .

HY-172686

DSPE-PEG1000-CSTSMLKAC		Pegylated Lipids
DSPE-PEG1000-CSTSMLKAC is a PEG compound which composed of DSPE and a peptide (CSTSMLKAC). CSTSMLKAC is capable of mediating selective homing of phage to ischemic heart tissue. DSPE-PEG1000-CSTSMLKAC can be used for drug delivery .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Ischemic

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products